<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><front><journal-meta><journal-id journal-id-type="nlm-ta">Evid Based Complement Alternat Med</journal-id><journal-id journal-id-type="iso-abbrev">Evid Based Complement Alternat Med</journal-id><journal-id journal-id-type="publisher-id">ECAM</journal-id><journal-title-group><journal-title>Evidence-based Complementary and Alternative Medicine : eCAM</journal-title></journal-title-group><issn pub-type="ppub">1741-427X</issn><issn pub-type="epub">1741-4288</issn><publisher><publisher-name>Hindawi</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">29441116</article-id><article-id pub-id-type="pmc">5758845</article-id><article-id pub-id-type="doi">10.1155/2017/8780325</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>Efficacy and Safety of Sipjeondaebo-Tang for Anorexia in Patients with Cancer: A Pilot, Randomized, Double-Blind, Placebo-Controlled Trial</article-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0002-7078-0079</contrib-id><name><surname>Cheon</surname><given-names>Chunhoo</given-names></name><xref ref-type="aff" rid="I1">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Yoo</surname><given-names>Jeong-Eun</given-names></name><xref ref-type="aff" rid="I2">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0003-3738-3239</contrib-id><name><surname>Yoo</surname><given-names>Hwa-Seung</given-names></name><xref ref-type="aff" rid="I2">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Cho</surname><given-names>Chong-Kwan</given-names></name><xref ref-type="aff" rid="I2">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Kang</surname><given-names>Sohyeon</given-names></name><xref ref-type="aff" rid="I1">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Kim</surname><given-names>Mia</given-names></name><xref ref-type="aff" rid="I3">
<sup>3</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0002-2141-3483</contrib-id><name><surname>Jang</surname><given-names>Bo-Hyoung</given-names></name><xref ref-type="aff" rid="I1">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Shin</surname><given-names>Yong-Cheol</given-names></name><xref ref-type="aff" rid="I1">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0002-2345-430X</contrib-id><name><surname>Ko</surname><given-names>Seong-Gyu</given-names></name><email>epiko@khu.ac.kr</email><xref ref-type="aff" rid="I1">
<sup>1</sup>
</xref></contrib></contrib-group><aff id="I1">
<sup>1</sup>Department of Preventive Medicine, Korean Medical College, Kyung Hee University, Seoul, Republic of Korea</aff><aff id="I2">
<sup>2</sup>Dunsan Korean Medicine Hospital of Daejeon University, Daejeon, Republic of Korea</aff><aff id="I3">
<sup>3</sup>Department of Cardiovascular and Neurologic Disease (Stroke Center), College of Korean Medicine, Kyung Hee University, Seoul, Republic of Korea</aff><author-notes><fn fn-type="other"><p>Academic Editor: Gorkem Kismali</p></fn></author-notes><pub-date pub-type="ppub"><year>2017</year></pub-date><pub-date pub-type="epub"><day>26</day><month>12</month><year>2017</year></pub-date><volume>2017</volume><elocation-id>8780325</elocation-id><history><date date-type="received"><day>31</day><month>7</month><year>2017</year></date><date date-type="rev-recd"><day>18</day><month>11</month><year>2017</year></date><date date-type="accepted"><day>6</day><month>12</month><year>2017</year></date></history><permissions><copyright-statement>Copyright © 2017 Chunhoo Cheon et al.</copyright-statement><copyright-year>2017</copyright-year><license xlink:href="https://creativecommons.org/licenses/by/4.0/"><license-p>This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><abstract><sec><title><offsets xml_i="4592" xml_f="4602" txt_i="11" txt_f="21">Background</offsets></title><p><offsets xml_i="4613" xml_f="4784" txt_i="22" txt_f="193"> Anorexia occurs in about half of cancer patients and is associated with high mortality rate. However, safe and long-term use of anorexia treatment is still an unmet need.</offsets></p></sec><sec><title><offsets xml_i="4806" xml_f="4816" txt_i="195" txt_f="205"> Objective</offsets></title><p><offsets xml_i="4827" xml_f="4979" txt_i="206" txt_f="358"> The purpose of the present study was to examine the feasibility of Sipjeondaebo-tang (Juzen-taiho-to, Shi-Quan-Da-Bu-Tang) for cancer-related anorexia.</offsets></p></sec><sec><title><offsets xml_i="5001" xml_f="5009" txt_i="360" txt_f="368"> Methods</offsets></title><p><offsets xml_i="5020" xml_f="5461" txt_i="369" txt_f="810"> A total of 32 participants with cancer anorexia were randomized to either Sipjeondaebo-tang group or placebo group. Participants were given 3 g of Sipjeondaebo-tang or placebo 3 times a day for 4 weeks. The primary outcome was a change in the Anorexia/Cachexia Subscale of Functional Assessment of Anorexia/Cachexia Therapy (FAACT). The secondary outcomes included Visual Analogue Scale (VAS) of anorexia, FAACT scale, and laboratory tests.</offsets></p></sec><sec><title><offsets xml_i="5483" xml_f="5491" txt_i="812" txt_f="820"> Results</offsets></title><p><offsets xml_i="5502" xml_f="5724" txt_i="821" txt_f="1043"> Anorexia and quality of life measured by FAACT and VAS were improved after 4 weeks of Sipjeondaebo-tang treatment. However, there was no significant difference between changes of Sipjeondaebo-tang group and placebo group.</offsets></p></sec><sec><title><offsets xml_i="5746" xml_f="5758" txt_i="1045" txt_f="1057"> Conclusions</offsets></title><p><offsets xml_i="5769" xml_f="5933" txt_i="1058" txt_f="1222"> Sipjeondaebo-tang appears to have potential benefit for anorexia management in patients with cancer. Further large-scale studies are needed to ensure the efficacy.</offsets></p></sec><sec><title><offsets xml_i="5955" xml_f="5974" txt_i="1224" txt_f="1243"> Trial Registration</offsets></title><p><offsets xml_i="5985" xml_f="6035" txt_i="1244" txt_f="1294"> This trial is registered with ClinicalTrials.gov </offsets><ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT02468141"><offsets xml_i="6126" xml_f="6137" txt_i="1294" txt_f="1305">NCT02468141</offsets></ext-link><offsets xml_i="6148" xml_f="6149" txt_i="1305" txt_f="1306">.</offsets></p></sec></abstract><funding-group><award-group><funding-source>Ministry of Health and Welfare</funding-source><award-id>HI12C1889</award-id></award-group></funding-group></article-meta></front><body><sec id="sec1"><title><offsets xml_i="6372" xml_f="6387" txt_i="1315" txt_f="1330">1. Introduction</offsets></title><p><offsets xml_i="6398" xml_f="6644" txt_i="1331" txt_f="1577">Anorexia is associated with high mortality rate in cancer patients, reduction in the effectiveness of anticancer therapy, reduced ability to perform activities of daily living, and lower quality of life in physical, mental, and social functions [</offsets><xref rid="B1" ref-type="bibr"><offsets xml_i="6675" xml_f="6676" txt_i="1577" txt_f="1578">1</offsets></xref><offsets xml_i="6683" xml_f="6814" txt_i="1578" txt_f="1709">]. It occurs in about half of cancer patients and is known to have the highest frequency in lung and upper digestive tract cancer [</offsets><xref rid="B2" ref-type="bibr"><offsets xml_i="6845" xml_f="6846" txt_i="1709" txt_f="1710">2</offsets></xref><offsets xml_i="6853" xml_f="6995" txt_i="1710" txt_f="1852">]. It is important to properly manage anorexia, because cancer-related anorexia negatively affects response to chemotherapy and radiotherapy [</offsets><xref rid="B3" ref-type="bibr"><offsets xml_i="7026" xml_f="7027" txt_i="1852" txt_f="1853">3</offsets></xref><offsets xml_i="7034" xml_f="7036" txt_i="1853" txt_f="1855">].</offsets></p><p><offsets xml_i="7043" xml_f="7136" txt_i="1856" txt_f="1949">There were case studies on the improvement of anorexia in cancer patients using acupuncture [</offsets><xref rid="B4" ref-type="bibr"><offsets xml_i="7167" xml_f="7168" txt_i="1949" txt_f="1950">4</offsets></xref><offsets xml_i="7175" xml_f="7194" txt_i="1950" txt_f="1969">] and acupressure [</offsets><xref rid="B5" ref-type="bibr"><offsets xml_i="7225" xml_f="7226" txt_i="1969" txt_f="1970">5</offsets></xref><offsets xml_i="7233" xml_f="7338" txt_i="1970" txt_f="2075">], and there was a clinical study of moxibustion treatment for anorexia in patients with thyroid cancer [</offsets><xref rid="B6" ref-type="bibr"><offsets xml_i="7369" xml_f="7370" txt_i="2075" txt_f="2076">6</offsets></xref><offsets xml_i="7377" xml_f="7822" txt_i="2076" txt_f="2521">]. Steroids, megestrol acetate, prokinetic agents (metoclopramide), ghrelin, melatonin, and so on are administered to treat cancerous anorexia state of cancer patients. Steroids can improve quality of life and appetite, but can only be used for a short period of time due to limitations of metabolism and infectious side effects. Megestrol acetate improves appetite but also has potential side effects such as water retention and vein embolism [</offsets><xref rid="B7" ref-type="bibr"><offsets xml_i="7853" xml_f="7854" txt_i="2521" txt_f="2522">7</offsets></xref><offsets xml_i="7861" xml_f="8006" txt_i="2522" txt_f="2667">]. In addition, prokinetic agents such as metoclopramide improve chronic nausea, but there is no apparently proven effect on improving appetite [</offsets><xref rid="B8" ref-type="bibr"><offsets xml_i="8037" xml_f="8038" txt_i="2667" txt_f="2668">8</offsets></xref><offsets xml_i="8045" xml_f="8156" txt_i="2668" txt_f="2779">]. It has been reported in a small number of cancer patients that ghrelin stimulates appetite and food intake [</offsets><xref rid="B9" ref-type="bibr"><offsets xml_i="8187" xml_f="8188" txt_i="2779" txt_f="2780">9</offsets></xref><offsets xml_i="8195" xml_f="8197" txt_i="2780" txt_f="2782">].</offsets></p><p><offsets xml_i="8204" xml_f="8476" txt_i="2783" txt_f="3055">Sipjeondaebo-tang (SJDBT, also known as Juzen-taiho-to in Japanese and Shi-Quan-Da-Bu-Tang in Chinese), one of the most commonly used traditional herbal medicines in Korea, is prescribed for patients with deficiency syndrome, suffering from anemia, fatigue, and anorexia [</offsets><xref rid="B10" ref-type="bibr"><offsets xml_i="8508" xml_f="8510" txt_i="3055" txt_f="3057">10</offsets></xref><offsets xml_i="8517" xml_f="8519" txt_i="3057" txt_f="3059">, </offsets><xref rid="B11" ref-type="bibr"><offsets xml_i="8551" xml_f="8553" txt_i="3059" txt_f="3061">11</offsets></xref><offsets xml_i="8560" xml_f="8617" txt_i="3061" txt_f="3118">]. SJDBT also has been known to have anticancer effects [</offsets><xref rid="B12" ref-type="bibr"><offsets xml_i="8649" xml_f="8651" txt_i="3118" txt_f="3120">12</offsets></xref><offsets xml_i="8658" xml_f="8771" txt_i="3120" txt_f="3233">], and in vivo study provided evidence on that SJDBT may be useful for patients with cancer associated anorexia [</offsets><xref rid="B13" ref-type="bibr"><offsets xml_i="8803" xml_f="8805" txt_i="3233" txt_f="3235">13</offsets></xref><offsets xml_i="8812" xml_f="8814" txt_i="3235" txt_f="3237">].</offsets></p><p><offsets xml_i="8821" xml_f="9272" txt_i="3238" txt_f="3689">The purpose of this study was to evaluate the effect and safety of SJDBT for anorexia in cancer patients by comparing the experimental group to placebo group using the Functional Assessment of Anorexia and Cachexia Treatment (FAACT; Anorexia/Cachexia Subscale [ACS], Functional Assessment of Cancer Therapy-General [FACT-G]), anorexia Visual Analogue Scale (VAS), weight, body mass index (BMI), adrenocorticotropic hormone (ACTH), and cortisol values.</offsets></p></sec><sec id="sec2"><title><offsets xml_i="9304" xml_f="9328" txt_i="3691" txt_f="3715">2. Materials and Methods</offsets></title><sec id="sec2.1"><title><offsets xml_i="9360" xml_f="9377" txt_i="3716" txt_f="3733">2.1. Study Design</offsets></title><p><offsets xml_i="9388" xml_f="9820" txt_i="3734" txt_f="4166">A randomized, double-blind, placebo-controlled trial was conducted at the Dunsan Korean Medicine Hospital of Daejeon University in Daejeon, Republic of Korea. The Institutional Review Board of the Dunsan Korean Medicine Hospital of Daejeon University approved the study (reference DJDSKH-15-03-2 (Ver. 2.0)). The study protocol of this study has already been published as a protocol paper and also registered in ClinicalTrials.gov (</offsets><ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT02468141"><offsets xml_i="9911" xml_f="9922" txt_i="4166" txt_f="4177">NCT02468141</offsets></ext-link><offsets xml_i="9933" xml_f="10028" txt_i="4177" txt_f="4272">) prior to the completion of the clinical trial. We followed the methods of Cheon et al. 2016 [</offsets><xref rid="B14" ref-type="bibr"><offsets xml_i="10060" xml_f="10062" txt_i="4272" txt_f="4274">14</offsets></xref><offsets xml_i="10069" xml_f="10568" txt_i="4274" txt_f="4773">]. The process actually performed was described in the present report. Written informed consent was obtained from each participant prior to the study procedures. Participants who fulfil the eligibility criteria were enrolled. The enrolled participants were randomly assigned to two parallel groups: the SJDBT group and placebo group with the allocation ratio of 1 : 1. Each participant was assessed for signs and symptoms of anorexia during the trial period. The participants flow chart is shown in </offsets><xref ref-type="fig" rid="fig1"><offsets xml_i="10600" xml_f="10608" txt_i="4773" txt_f="4781">Figure 1</offsets></xref><offsets xml_i="10615" xml_f="10616" txt_i="4781" txt_f="4782">.</offsets></p><p><offsets xml_i="10623" xml_f="10988" txt_i="4783" txt_f="5148">This study was a pilot study that examines the feasibility for a full randomized clinical trial of SJDBT for treating cancer-related anorexia and determines the effect size for further large-scale studies. Thus, a total of 32 participants were recruited for the study. Sixteen participants were allocated to the SJDBT group and another sixteen to the placebo group.</offsets></p><p><offsets xml_i="10995" xml_f="11215" txt_i="5149" txt_f="5369">SJDBT and placebo were produced and packaged by Hanpoong Pharm and Foods Co., Ltd., the pharmaceutical company, certified GMP (Good Manufacturing Practice) by the Ministry of Food and Drug Safety of Korea. SJDBT includes</offsets><italic><offsets xml_i="11223" xml_f="11240" txt_i="5369" txt_f="5386"> Cinnamomi Cortex</offsets></italic><offsets xml_i="11249" xml_f="11259" txt_i="5386" txt_f="5396"> (1.00 g),</offsets><italic><offsets xml_i="11267" xml_f="11282" txt_i="5396" txt_f="5411"> Paeoniae Radix</offsets></italic><offsets xml_i="11291" xml_f="11301" txt_i="5411" txt_f="5421"> (1.00 g),</offsets><italic><offsets xml_i="11309" xml_f="11335" txt_i="5421" txt_f="5447"> Atractylodis Rhizoma Alba</offsets></italic><offsets xml_i="11344" xml_f="11354" txt_i="5447" txt_f="5457"> (1.00 g),</offsets><italic><offsets xml_i="11362" xml_f="11381" txt_i="5457" txt_f="5476"> Ginseng Radix Alba</offsets></italic><offsets xml_i="11390" xml_f="11400" txt_i="5476" txt_f="5486"> (1.00 g),</offsets><italic><offsets xml_i="11408" xml_f="11423" txt_i="5486" txt_f="5501"> Cnidii Rhizoma</offsets></italic><offsets xml_i="11432" xml_f="11442" txt_i="5501" txt_f="5511"> (1.00 g),</offsets><italic><offsets xml_i="11450" xml_f="11466" txt_i="5511" txt_f="5527"> Astragali Radix</offsets></italic><offsets xml_i="11475" xml_f="11485" txt_i="5527" txt_f="5537"> (1.00 g),</offsets><italic><offsets xml_i="11493" xml_f="11510" txt_i="5537" txt_f="5554"> Poria Sclerotium</offsets></italic><offsets xml_i="11519" xml_f="11529" txt_i="5554" txt_f="5564"> (1.00 g),</offsets><italic><offsets xml_i="11537" xml_f="11564" txt_i="5564" txt_f="5591"> Rehmanniae Radix Preparata</offsets></italic><offsets xml_i="11573" xml_f="11583" txt_i="5591" txt_f="5601"> (1.00 g),</offsets><italic><offsets xml_i="11591" xml_f="11616" txt_i="5601" txt_f="5626"> Angelicae Gigantis Radix</offsets></italic><offsets xml_i="11625" xml_f="11639" txt_i="5626" txt_f="5640"> (1.00 g), and</offsets><italic><offsets xml_i="11647" xml_f="11666" txt_i="5640" txt_f="5659"> Glycyrrhizae Radix</offsets></italic><offsets xml_i="11675" xml_f="12032" txt_i="5659" txt_f="6016"> (0.5 g). These raw materials were extracted and concentrated to 3 grams for single dose. The placebo was made of lactose, corn starch, and caramel colouring, and it had similar appearance, shape, weight, taste, and colour to SJDBT. Investigational products were manufactured in accordance with the Korean herbal pharmacopoeia and the Korean pharmacopoeia [</offsets><xref rid="B15" ref-type="bibr"><offsets xml_i="12064" xml_f="12066" txt_i="6016" txt_f="6018">15</offsets></xref><offsets xml_i="12073" xml_f="12075" txt_i="6018" txt_f="6020">, </offsets><xref rid="B16" ref-type="bibr"><offsets xml_i="12107" xml_f="12109" txt_i="6020" txt_f="6022">16</offsets></xref><offsets xml_i="12116" xml_f="12343" txt_i="6022" txt_f="6249">]. Brief description is as follows: Each herbal medicine of SJDBT and 10-fold volume of purified water are put into an extractor and extracted at 100°C for 3 hours. The extract is filtered using a microfilter with a size of 25 </offsets><italic><offsets xml_i="12351" xml_f="12352" txt_i="6249" txt_f="6250">μ</offsets></italic><offsets xml_i="12361" xml_f="12471" txt_i="6250" txt_f="6360">m, and the filtrate is concentrated under reduced pressure at 60°C or lower and dried to obtain dried extract.</offsets></p><p><offsets xml_i="12478" xml_f="13033" txt_i="6361" txt_f="6916">The participants received SJDBT or a placebo drug for four weeks. They orally took 3 grams of granules with water three times a day after meals for 4 weeks. The participants were required to return the remaining drug for calculating compliance at visit 3 and visit 4. During the trial, the participants were prohibited to receive other treatments for anorexia. All treatments were documented on the case report form (CRF), including the drug name, the daily dose, the purpose of the drug use, the route of administration, and the start date and stop date.</offsets></p></sec><sec id="sec2.2"><title><offsets xml_i="13067" xml_f="13084" txt_i="6918" txt_f="6935">2.2. Participants</offsets></title><p><offsets xml_i="13095" xml_f="13351" txt_i="6936" txt_f="7192">Regardless of the type and stage of cancer, all patients with solid cancer complaining of anorexia have been subject to recruitment. Participants were recruited regardless of chemotherapy and radiotherapy. The inclusion and exclusion criteria are shown in </offsets><xref ref-type="fig" rid="figbox1"><offsets xml_i="13386" xml_f="13391" txt_i="7192" txt_f="7197">Box 1</offsets></xref><offsets xml_i="13398" xml_f="13399" txt_i="7197" txt_f="7198">.</offsets></p></sec><sec id="sec2.3"><title><offsets xml_i="13433" xml_f="13464" txt_i="7200" txt_f="7231">2.3. Randomization and Blinding</offsets></title><p><offsets xml_i="13475" xml_f="14263" txt_i="7232" txt_f="8020">Institute of Safety, Efficacy and Effectiveness Evaluation for Korean Medicine (ISEE) which was the Contract Research Organization (CRO) of the present study generated random numbers. Block randomization with block size of four was performed. The random numbers and randomization table were maintained by the ISEE during the research period in opaque and sealed envelopes. The opening procedure followed the Standard Operating Procedures (SOPs). A research assistant who was not involved in recruitment, intervention, or assessment of outcomes prepared the envelopes. Investigators responsible for recruitment and assessment were not allowed to take part in the group allocation. Therefore, all the investigators, monitors, and participants were blinded for assignment of the study drugs.</offsets></p></sec><sec id="sec2.4"><title><offsets xml_i="14297" xml_f="14323" txt_i="8022" txt_f="8048">2.4. Efficacy Measurements</offsets></title><p><offsets xml_i="14334" xml_f="14472" txt_i="8049" txt_f="8187">The change in the ACS of FAACT between the baseline (visit 2) and end of the study (visit 4) was used as the primary outcome measurement [</offsets><xref rid="B17" ref-type="bibr"><offsets xml_i="14504" xml_f="14506" txt_i="8187" txt_f="8189">17</offsets></xref><offsets xml_i="14513" xml_f="14591" txt_i="8189" txt_f="8267">]. Secondary outcome measurements were as follows: the changes in the FACT-G [</offsets><xref rid="B17" ref-type="bibr"><offsets xml_i="14623" xml_f="14625" txt_i="8267" txt_f="8269">17</offsets></xref><offsets xml_i="14632" xml_f="14691" txt_i="8269" txt_f="8328">], anorexia VAS, qi deficiency and blood deficiency scale [</offsets><xref rid="B18" ref-type="bibr"><offsets xml_i="14723" xml_f="14725" txt_i="8328" txt_f="8330">18</offsets></xref><offsets xml_i="14732" xml_f="15084" txt_i="8330" txt_f="8682">], and clinical laboratory tests including ACTH, cortisol, ghrelin, IL-6, erythrocyte sedimentation rate (ESR), and c-reactive protein (CRP). Blood and urine specimens were collected for haematological test, biochemistry test, and urinalysis at visit 1, visit 2, and visit 4. The specimens were analysed in the clinical laboratory of trial institution.</offsets></p></sec><sec id="sec2.5"><title><offsets xml_i="15118" xml_f="15141" txt_i="8684" txt_f="8707">2.5. Safety Measurement</offsets></title><p><offsets xml_i="15152" xml_f="15389" txt_i="8708" txt_f="8945">At every visit, vital signs including blood pressure, pulse, respiration rate, and physical examination, haematologic test, biochemical test, and urine test related to safety assessment and any adverse events were documented in the CRFs.</offsets></p></sec><sec id="sec2.6"><title><offsets xml_i="15423" xml_f="15448" txt_i="8947" txt_f="8972">2.6. Statistical Analysis</offsets></title><p><offsets xml_i="15459" xml_f="15633" txt_i="8973" txt_f="9147">All statistical procedures were performed using the R statistical software (version 3.2.5; R Foundation for Statistical Computing, Vienna, Austria). A two-sided, 5% or lower </offsets><italic><offsets xml_i="15641" xml_f="15642" txt_i="9147" txt_f="9148">p</offsets></italic><offsets xml_i="15651" xml_f="15903" txt_i="9148" txt_f="9400"> value was considered statistically significant. ITT (intention-to-treat, all randomly assigned participants) data set was applied for data analysis. The continuous variables were displayed as mean ± SD, and the categorical variables were displayed as </offsets><italic><offsets xml_i="15911" xml_f="15912" txt_i="9400" txt_f="9401">n</offsets></italic><offsets xml_i="15921" xml_f="16082" txt_i="9401" txt_f="9562"> (%). The baseline characteristics were compared to see whether there is a significant difference between SJDBT group and placebo group by either an independent </offsets><italic><offsets xml_i="16090" xml_f="16091" txt_i="9562" txt_f="9563">t</offsets></italic><offsets xml_i="16100" xml_f="16271" txt_i="9563" txt_f="9734">-test for continuous variables including age, height, weight, BMI, FAACT scale, anorexia VAS, SBP, DBP, pulse, ACTH, cortisol, ghrelin, interleukin 6, ESR, and CRP or the </offsets><italic><offsets xml_i="16279" xml_f="16280" txt_i="9734" txt_f="9735">χ</offsets></italic><sup><offsets xml_i="16294" xml_f="16295" txt_i="9735" txt_f="9736">2</offsets></sup><offsets xml_i="16301" xml_f="16521" txt_i="9736" txt_f="9956"> test for the categorical data including gender, cancer type, and anticancer therapy. For the efficacy variables, the mean differences between the baseline and the end of the treatment were compared using an independent </offsets><italic><offsets xml_i="16529" xml_f="16530" txt_i="9956" txt_f="9957">t</offsets></italic><offsets xml_i="16539" xml_f="16726" txt_i="9957" txt_f="10144">-test. Two-way repeated measured analysis of variance was also used to determine differences between the groups and over time. The normality assumption was tested using Shapiro-Wilk test.</offsets></p></sec></sec><sec id="sec3"><title><offsets xml_i="16764" xml_f="16774" txt_i="10147" txt_f="10157">3. Results</offsets></title><p><offsets xml_i="16785" xml_f="17804" txt_i="10158" txt_f="11177">Of all the 32 randomized participants, 16 participants (50%) took SJDBT and 16 participants (50%) took placebo. There were 14 thyroid cancer, 7 breast cancer, 4 lung cancer, 2 breast cancer, 2 colon cancer, and 2 cervical cancer participants. Of the total 32 participants, 3 participants received both chemotherapy and radiation therapy, 7 participants received chemotherapy only, 9 participants received radiotherapy only, and 13 participants did not receive both chemotherapy and radiation therapy. In SJDBT group, there was one participant lost to follow-up for low compliance. In placebo group, there were two participants lost to follow-up who withdrew the informed consent. No one dropped out before receiving the intervention. Thus, 16 participants treated with SJDBT and 16 participants treated with placebo were included in the ITT analyses. After 4 weeks, 15 participants completed the trial in the SJDBT group and 14 participants completed the trial in the placebo group. Participants flow chart is shown in </offsets><xref ref-type="fig" rid="fig1"><offsets xml_i="17836" xml_f="17844" txt_i="11177" txt_f="11185">Figure 1</offsets></xref><offsets xml_i="17851" xml_f="17852" txt_i="11185" txt_f="11186">.</offsets></p><sec id="sec3.1"><title><offsets xml_i="17880" xml_f="17909" txt_i="11187" txt_f="11216">3.1. Baseline Characteristics</offsets></title><p><offsets xml_i="17920" xml_f="17981" txt_i="11217" txt_f="11278">The baseline characteristics of the two groups were shown in </offsets><xref ref-type="table" rid="tab1"><offsets xml_i="18015" xml_f="18022" txt_i="11278" txt_f="11285">Table 1</offsets></xref><offsets xml_i="18029" xml_f="18291" txt_i="11285" txt_f="11547">. Baseline characteristics were similar in the two groups. There were no statistically significant differences between the SJDBT group and placebo group with respect to age, sex, height, weight, BMI, FAACT scale, anorexia VAS, vital signs, and laboratory tests (</offsets><italic><offsets xml_i="18299" xml_f="18300" txt_i="11547" txt_f="11548">p</offsets></italic><offsets xml_i="18309" xml_f="18321" txt_i="11548" txt_f="11557"> &gt; 0.05).</offsets></p></sec><sec id="sec3.2"><title><offsets xml_i="18355" xml_f="18376" txt_i="11559" txt_f="11580">3.2. Primary Outcomes</offsets></title><sec id="sec3.2.1"><title><offsets xml_i="18410" xml_f="18426" txt_i="11581" txt_f="11597">3.2.1. FAACT ACS</offsets></title><p><offsets xml_i="18437" xml_f="18493" txt_i="11598" txt_f="11654">The mean FAACT ACS score at each time point is shown in </offsets><xref ref-type="table" rid="tab2"><offsets xml_i="18527" xml_f="18534" txt_i="11654" txt_f="11661">Table 2</offsets></xref><offsets xml_i="18541" xml_f="18782" txt_i="11661" txt_f="11902">. The changes in the Anorexia/Cachexia Subscale of FAACT between baseline and the end of study were −4.63 in SJDBT group and −2.75 in placebo group, but the changes of FAACT ACS score were not significantly different between the two groups (</offsets><italic><offsets xml_i="18790" xml_f="18791" txt_i="11902" txt_f="11903">p</offsets></italic><offsets xml_i="18800" xml_f="18912" txt_i="11903" txt_f="12015"> = 0.245). In the within-group analysis, change in SJDBT group and placebo group showed significant difference (</offsets><italic><offsets xml_i="18920" xml_f="18921" txt_i="12015" txt_f="12016">p</offsets></italic><offsets xml_i="18930" xml_f="18946" txt_i="12016" txt_f="12029"> &lt; 0.001 and </offsets><italic><offsets xml_i="18954" xml_f="18955" txt_i="12029" txt_f="12030">p</offsets></italic><offsets xml_i="18964" xml_f="19080" txt_i="12030" txt_f="12146"> = 0.025, SJDBT group and placebo group, resp.). There was no statistically significant group-by-period interaction.</offsets></p></sec></sec><sec id="sec3.3"><title><offsets xml_i="19120" xml_f="19143" txt_i="12149" txt_f="12172">3.3. Secondary Outcomes</offsets></title><sec id="sec3.3.1"><title><offsets xml_i="19177" xml_f="19206" txt_i="12173" txt_f="12202">3.3.1. FAACT and Anorexia VAS</offsets></title><p><offsets xml_i="19217" xml_f="19292" txt_i="12203" txt_f="12278">The mean FAACT score and anorexia VAS at each time point are also shown in </offsets><xref ref-type="table" rid="tab2"><offsets xml_i="19326" xml_f="19333" txt_i="12278" txt_f="12285">Table 2</offsets></xref><offsets xml_i="19340" xml_f="19554" txt_i="12285" txt_f="12499">. The changes in the FAACT score between baseline and the end of study were −14.13 in SJDBT group and −7.38 in placebo group, but the changes of FAACT score were not significantly different between the two groups (</offsets><italic><offsets xml_i="19562" xml_f="19563" txt_i="12499" txt_f="12500">p</offsets></italic><offsets xml_i="19572" xml_f="19684" txt_i="12500" txt_f="12612"> = 0.124). In the within-group analysis, change in SJDBT group and placebo group showed significant difference (</offsets><italic><offsets xml_i="19692" xml_f="19693" txt_i="12612" txt_f="12613">p</offsets></italic><offsets xml_i="19702" xml_f="19718" txt_i="12613" txt_f="12626"> &lt; 0.001 and </offsets><italic><offsets xml_i="19726" xml_f="19727" txt_i="12626" txt_f="12627">p</offsets></italic><offsets xml_i="19736" xml_f="19998" txt_i="12627" txt_f="12889"> = 0.011, SJDBT group and placebo group, resp.). The changes in the anorexia VAS between baseline and the end of study were 25.78 in SJDBT group and 18.45 in placebo group, but the changes of anorexia VAS were not significantly different between the two groups (</offsets><italic><offsets xml_i="20006" xml_f="20007" txt_i="12889" txt_f="12890">p</offsets></italic><offsets xml_i="20016" xml_f="20128" txt_i="12890" txt_f="13002"> = 0.346). In the within-group analysis, change in SJDBT group and placebo group showed significant difference (</offsets><italic><offsets xml_i="20136" xml_f="20137" txt_i="13002" txt_f="13003">p</offsets></italic><offsets xml_i="20146" xml_f="20162" txt_i="13003" txt_f="13016"> &lt; 0.001 and </offsets><italic><offsets xml_i="20170" xml_f="20171" txt_i="13016" txt_f="13017">p</offsets></italic><offsets xml_i="20180" xml_f="20298" txt_i="13017" txt_f="13135"> = 0.001, SJDBT group and placebo group, resp.). There were no statistically significant group-by-period interactions.</offsets></p></sec><sec id="sec3.3.2"><title><offsets xml_i="20334" xml_f="20366" txt_i="13137" txt_f="13169">3.3.2. Clinical Laboratory Tests</offsets></title><p><offsets xml_i="20377" xml_f="20551" txt_i="13170" txt_f="13344">In between-group analysis, the change of ACTH, cortisol, ghrelin, IL-6, ESR, and CRP between baseline and the end of study did not show statistically significant difference (</offsets><xref ref-type="table" rid="tab3"><offsets xml_i="20585" xml_f="20592" txt_i="13344" txt_f="13351">Table 3</offsets></xref><offsets xml_i="20599" xml_f="20694" txt_i="13351" txt_f="13446">). In within-group analysis, all clinical laboratory tests did not show significant difference.</offsets></p></sec><sec id="sec3.3.3"><title><offsets xml_i="20730" xml_f="20777" txt_i="13448" txt_f="13495">3.3.3. Qi Deficiency and Blood Deficiency Scale</offsets></title><p><offsets xml_i="20788" xml_f="20966" txt_i="13496" txt_f="13674">In between-group analysis, the changes of qi deficiency scale and blood deficiency scale between baseline and end of the study did not show statistically significant difference (</offsets><xref ref-type="table" rid="tab4"><offsets xml_i="21000" xml_f="21007" txt_i="13674" txt_f="13681">Table 4</offsets></xref><offsets xml_i="21014" xml_f="21200" txt_i="13681" txt_f="13867">). In within-group analysis, qi deficiency scale showed significant changes in both of SJDBT group and placebo group, and blood deficiency scale showed significant change in SJDBT group.</offsets></p></sec></sec><sec id="sec3.4"><title><offsets xml_i="21240" xml_f="21260" txt_i="13870" txt_f="13890">3.4. Safety Analysis</offsets></title><p><offsets xml_i="21271" xml_f="21484" txt_i="13891" txt_f="14104">At every visit, systolic blood pressure (SBP), diastolic blood pressure (DBP), pulse, AST, ALT, blood urea nitrogen (BUN), and creatinine did not show significant difference between SJDBT group and placebo group (</offsets><xref ref-type="table" rid="tab5"><offsets xml_i="21518" xml_f="21525" txt_i="14104" txt_f="14111">Table 5</offsets></xref><offsets xml_i="21532" xml_f="21814" txt_i="14111" txt_f="14393">). In within-group analysis, at 2 weeks, DBP decreased in the placebo group and, at 4 weeks, DBP decreased in the SJDBT group. There was no noteworthy difference between the SJDBT group and placebo group. Some statistically significant changes in DBP were not in the abnormal range.</offsets></p></sec></sec><sec id="sec4"><title><offsets xml_i="21852" xml_f="21865" txt_i="14396" txt_f="14409">4. Discussion</offsets></title><p><offsets xml_i="21876" xml_f="22534" txt_i="14410" txt_f="15068">The present study is double-blind, randomized, placebo-controlled trial that investigated whether SJDBT improves appetite loss measured by FAACT ACS score and anorexia VAS in cancer patients with anorexia after 4 weeks of treatment. However, there was no statistically significant difference between the SJDBT group and placebo group. In addition to appetite loss, general aspect in quality of life measured by FAACT was also assessed after 4 weeks of treatment. But, there was no statistically significant difference between two groups. Otherwise, changes of clinical laboratory tests including ACTH, cortisol, ghrelin, IL-6, ESR, and CRP were unremarkable.</offsets></p><p><offsets xml_i="22541" xml_f="22943" txt_i="15069" txt_f="15471">Although there was no statistically significant difference between SJDBT group and placebo group, the changes of FAACT and anorexia VAS in the SJDBT group imply the need for large-scale trial in further studies. Given that the aspect of change of total FAACT score is similar to that of FAACT ACS score, further studies need to focus on not only the anorexia but also overall status of cancer patients.</offsets></p><p><offsets xml_i="22950" xml_f="23156" txt_i="15472" txt_f="15678">There was a report that Rikkunshito which is often prescribed for the treatment of anorexia regulates ghrelin secretion and degradation, sensitizes ghrelin receptor, and antagonizes the 5-HT2b/c receptors [</offsets><xref rid="B19" ref-type="bibr"><offsets xml_i="23188" xml_f="23190" txt_i="15678" txt_f="15680">19</offsets></xref><offsets xml_i="23197" xml_f="23538" txt_i="15680" txt_f="16021">]. However, in the present study, SJDBT did not affect the concentration of ghrelin. It is speculated that these two herbal medicines have different mechanisms on anorexia. The previous study suggested that SJDBT regulates levels of glucagon-like peptide-1 (GLP-1) and peptide tyrosine tyrosine (PYY) which are satiety stimulators in serum [</offsets><xref rid="B13" ref-type="bibr"><offsets xml_i="23570" xml_f="23572" txt_i="16021" txt_f="16023">13</offsets></xref><offsets xml_i="23579" xml_f="23581" txt_i="16023" txt_f="16025">, </offsets><xref rid="B20" ref-type="bibr"><offsets xml_i="23613" xml_f="23615" txt_i="16025" txt_f="16027">20</offsets></xref><offsets xml_i="23622" xml_f="23624" txt_i="16027" txt_f="16029">, </offsets><xref rid="B21" ref-type="bibr"><offsets xml_i="23656" xml_f="23658" txt_i="16029" txt_f="16031">21</offsets></xref><offsets xml_i="23665" xml_f="23766" txt_i="16031" txt_f="16132">]. Therefore, in further clinical studies, effects of SJDBT on GLP-1 and PYY need to be investigated.</offsets></p><p><offsets xml_i="23773" xml_f="23982" txt_i="16133" txt_f="16342">Although the present study did not show statistically significant difference between SJDBT and placebo, previous preclinical study reported that SJDBT improves cancer-induced weight loss and anorexia in mice [</offsets><xref rid="B13" ref-type="bibr"><offsets xml_i="24014" xml_f="24016" txt_i="16342" txt_f="16344">13</offsets></xref><offsets xml_i="24023" xml_f="24129" txt_i="16344" txt_f="16450">]. Moreover, in preclinical studies, SJDBT improved immunological function and had antiangiogenic action [</offsets><xref rid="B22" ref-type="bibr"><offsets xml_i="24161" xml_f="24163" txt_i="16450" txt_f="16452">22</offsets></xref><offsets xml_i="24170" xml_f="24172" txt_i="16452" txt_f="16454">, </offsets><xref rid="B23" ref-type="bibr"><offsets xml_i="24204" xml_f="24206" txt_i="16454" txt_f="16456">23</offsets></xref><offsets xml_i="24213" xml_f="24279" txt_i="16456" txt_f="16522">], inhibited cancer cell metastasis by inducing NK cell activity [</offsets><xref rid="B24" ref-type="bibr"><offsets xml_i="24311" xml_f="24313" txt_i="16522" txt_f="16524">24</offsets></xref><offsets xml_i="24320" xml_f="24361" txt_i="16524" txt_f="16565">], suppressed enlargement of tumor size [</offsets><xref rid="B25" ref-type="bibr"><offsets xml_i="24393" xml_f="24395" txt_i="16565" txt_f="16567">25</offsets></xref><offsets xml_i="24402" xml_f="24464" txt_i="16567" txt_f="16629">], and alleviated bone marrow suppression by anticancer drug [</offsets><xref rid="B26" ref-type="bibr"><offsets xml_i="24496" xml_f="24498" txt_i="16629" txt_f="16631">26</offsets></xref><offsets xml_i="24505" xml_f="24609" txt_i="16631" txt_f="16735">]. In clinical studies, SJDBT ameliorated anemia which is a frequent complaint of patients with cancer [</offsets><xref rid="B27" ref-type="bibr"><offsets xml_i="24641" xml_f="24643" txt_i="16735" txt_f="16737">27</offsets></xref><offsets xml_i="24650" xml_f="24726" txt_i="16737" txt_f="16813">], improved quality of life in patients with cancer receiving chemotherapy [</offsets><xref rid="B28" ref-type="bibr"><offsets xml_i="24758" xml_f="24760" txt_i="16813" txt_f="16815">28</offsets></xref><offsets xml_i="24767" xml_f="24852" txt_i="16815" txt_f="16900">], and showed immune enhancement effect in patients with advanced pancreatic cancer [</offsets><xref rid="B29" ref-type="bibr"><offsets xml_i="24884" xml_f="24886" txt_i="16900" txt_f="16902">29</offsets></xref><offsets xml_i="24893" xml_f="25014" txt_i="16902" txt_f="17023">]. Thus, a comprehensive approach and further studies are needed to utilize SJDBT for management of patients with cancer.</offsets></p><p><offsets xml_i="25021" xml_f="25250" txt_i="17024" txt_f="17253">Qi deficiency leads to decreased visceral functions and lowered body resistance and blood deficiency is any pathological change characterized by deficiency of blood which fails to nourish organs, tissues, and meridians/channels [</offsets><xref rid="B30" ref-type="bibr"><offsets xml_i="25282" xml_f="25284" txt_i="17253" txt_f="17255">30</offsets></xref><offsets xml_i="25291" xml_f="25434" txt_i="17255" txt_f="17398">]. In the present study, qi deficiency and blood deficiency were improved in both groups and there was no statistically significant difference.</offsets></p><p><offsets xml_i="25441" xml_f="25466" txt_i="17399" txt_f="17424">It has been reported that</offsets><italic><offsets xml_i="25474" xml_f="25490" txt_i="17424" txt_f="17440"> Astragali Radix</offsets></italic><offsets xml_i="25499" xml_f="25549" txt_i="17440" txt_f="17490"> and ginsenoside Rg1 which is a major component of</offsets><italic><offsets xml_i="25557" xml_f="25571" txt_i="17490" txt_f="17504"> Ginseng Radix</offsets></italic><offsets xml_i="25580" xml_f="25619" txt_i="17504" txt_f="17543"> have a beneficial effect on anorexia [</offsets><xref rid="B31" ref-type="bibr"><offsets xml_i="25651" xml_f="25653" txt_i="17543" txt_f="17545">31</offsets></xref><offsets xml_i="25660" xml_f="25662" txt_i="17545" txt_f="17547">, </offsets><xref rid="B32" ref-type="bibr"><offsets xml_i="25694" xml_f="25696" txt_i="17547" txt_f="17549">32</offsets></xref><offsets xml_i="25703" xml_f="25825" txt_i="17549" txt_f="17671">]. However, most of the mechanisms of the active compounds of herbal medicine used in anorexia treatments remain unclear [</offsets><xref rid="B33" ref-type="bibr"><offsets xml_i="25857" xml_f="25859" txt_i="17671" txt_f="17673">33</offsets></xref><offsets xml_i="25866" xml_f="26003" txt_i="17673" txt_f="17810">]. Likewise, molecular mechanisms of compounds in SJDBT also remain unknown and these are major challenges for herbal medicine research [</offsets><xref rid="B34" ref-type="bibr"><offsets xml_i="26035" xml_f="26037" txt_i="17810" txt_f="17812">34</offsets></xref><offsets xml_i="26044" xml_f="26046" txt_i="17812" txt_f="17814">].</offsets></p><p><offsets xml_i="26053" xml_f="27863" txt_i="17815" txt_f="19625">There were some limitations of the present study. The sample size was too small to show statistically significant results. However, the results of the present pilot study will be used for designing the main study. The purpose of this study was to evaluate efficacy of SJDBT for anorexia; thus we only prohibited participants from taking medications that aim to improve appetite, not for other purposes; therefore many participants took herbal medicines which could affect the qi deficiency and blood deficiency for treatment of fatigue or pain, and so on. This has made it difficult to assess the effects of SJDBT on qi deficiency and blood deficiency. It was an inevitable choice for the needs of patients using Korean medicine hospital and for facilitating clinical trial recruitment. For a similar reason, all patients with solid cancer complaining of anorexia were recruited and the number of participants was too small to investigate the difference in the effect of SJDBT and the difference of anorexia according to cancer type. Another limitation of the present study is that the type of chemotherapy drugs was not confirmed and thus we could not confirm the difference of effect of SJDBT according to the type of chemotherapy. This is because the participants received primary treatment of cancer from other medical institutions, and then the study was conducted on participants who visited the trial institution for symptoms management. Although these limitations limit the interpretation of the study results, the present study is meaningful in that such pilot study results are necessary to conduct large-scale, rigorous study in the medical reality in Korea. Rigorous further studies which compensate these defects will be necessary to ascertain the efficacy of SJDBT for anorexia in cancer patient.</offsets></p></sec><sec id="sec5"><title><offsets xml_i="27895" xml_f="27909" txt_i="19627" txt_f="19641">5. Conclusions</offsets></title><p><offsets xml_i="27920" xml_f="28349" txt_i="19642" txt_f="20071">The present pilot study showed the feasibility that SJDBT could be used for management of patients with cancer. Compared to baseline, 4 weeks of SJDBT treatment improved the quality of life assessed by the FAACT and anorexia in patients with cancer. However, there was no statistically significant difference between SJDBT group and placebo group. These findings could be used as preliminary data for further large-scale studies.</offsets></p></sec></body><back><ack><title>Acknowledgments</title><p>This research was supported by the Korea Health Technology R&amp;D Project through the Korea Health Industry Development Institute (KHIDI), funded by the Ministry of Health &amp; Welfare, Republic of Korea (Grant no. HI12C1889).</p></ack><glossary><title>Abbreviations</title><def-list><def-item><term>SJDBT:</term><def><p>Sipjeondaebo-tang</p></def></def-item><def-item><term>FAACT:</term><def><p>Functional Assessment of Anorexia and Cachexia Treatment</p></def></def-item><def-item><term>ACS:</term><def><p>Anorexia/Cachexia Subscale</p></def></def-item><def-item><term>FACT-G:</term><def><p>Functional Assessment of Cancer Therapy-General</p></def></def-item><def-item><term>VAS:</term><def><p>Visual Analogue Scale</p></def></def-item><def-item><term>BMI:</term><def><p>Body mass index</p></def></def-item><def-item><term>ACTH:</term><def><p>Adrenocorticotropic hormone</p></def></def-item><def-item><term>ALT:</term><def><p>Alanine aminotransferase</p></def></def-item><def-item><term>AST:</term><def><p>Aspartate aminotransferase</p></def></def-item><def-item><term>ECOG:</term><def><p>Eastern Cooperative Oncology Group</p></def></def-item><def-item><term>ISEE:</term><def><p>Institute of Safety, Efficacy and Effectiveness Evaluation for Korean Medicine</p></def></def-item><def-item><term>CRO:</term><def><p>Contract Research Organization</p></def></def-item><def-item><term>SOPs:</term><def><p>Standard Operating Procedures</p></def></def-item><def-item><term>ESR:</term><def><p>Erythrocyte sedimentation rate</p></def></def-item><def-item><term>CRP:</term><def><p>c-reactive protein</p></def></def-item><def-item><term>CRF:</term><def><p>Case report form</p></def></def-item><def-item><term>ITT:</term><def><p>Intention-to-treat</p></def></def-item><def-item><term>SBP:</term><def><p>Systolic blood pressure</p></def></def-item><def-item><term>DBP:</term><def><p>Diastolic blood pressure</p></def></def-item><def-item><term>BUN:</term><def><p>Blood urea nitrogen</p></def></def-item><def-item><term>GLP-1:</term><def><p>Glucagon-like peptide-1</p></def></def-item><def-item><term>PYY:</term><def><p>Peptide tyrosine tyrosine.</p></def></def-item></def-list></glossary><sec><title>Conflicts of Interest</title><p>The authors declare that they have no conflicts of interest.</p></sec><sec><title>Authors' Contributions</title><p>Chunhoo Cheon and Jeong-Eun Yoo have drafted the manuscript. Sohyeon Kang, Mia Kim, and Bo-Hyoung Jang have edited the manuscript. Hwa-Seung Yoo, Chong-Kwan Cho, and Yong-Cheol Shin have supervised the study. Seong-Gyu Ko has conducted all the required procedures under the protocol. Chunhoo Cheon and Jeong-Eun Yoo have equally contributed to this work.</p></sec><ref-list><ref id="B1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brown</surname><given-names>J. K.</given-names></name></person-group><article-title>A systematic review of the evidence on symptom management of cancer-related anorexia and cachexia</article-title><source><italic>Oncology Nursing Forum</italic></source><year>2002</year><volume>29</volume><issue>3</issue><fpage>517</fpage><lpage>532</lpage><pub-id pub-id-type="doi">10.1188/02.ONF.517-532</pub-id><pub-id pub-id-type="pmid">11979284</pub-id></element-citation></ref><ref id="B2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fearon</surname><given-names>K. C. H.</given-names></name><name><surname>Moses</surname><given-names>A. G. W.</given-names></name></person-group><article-title>Cancer cachexia</article-title><source><italic>International Journal of Cardiology</italic></source><year>2002</year><volume>85</volume><issue>1</issue><fpage>73</fpage><lpage>81</lpage><pub-id pub-id-type="doi">10.1016/s0167-5273(02)00235-8</pub-id><pub-id pub-id-type="other">2-s2.0-0036342364</pub-id><pub-id pub-id-type="pmid">12163211</pub-id></element-citation></ref><ref id="B3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Muscaritoli</surname><given-names>M.</given-names></name><name><surname>Bossola</surname><given-names>M.</given-names></name><name><surname>Aversa</surname><given-names>Z.</given-names></name><name><surname>Bellantone</surname><given-names>R.</given-names></name><name><surname>Rossi Fanelli</surname><given-names>F.</given-names></name></person-group><article-title>Prevention and treatment of cancer cachexia: new insights into an old problem</article-title><source><italic>European Journal of Cancer</italic></source><year>2006</year><volume>42</volume><issue>1</issue><fpage>31</fpage><lpage>41</lpage><pub-id pub-id-type="doi">10.1016/j.ejca.2005.07.026</pub-id><pub-id pub-id-type="other">2-s2.0-29144513918</pub-id><pub-id pub-id-type="pmid">16314085</pub-id></element-citation></ref><ref id="B4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ezzo</surname><given-names>J. M.</given-names></name><name><surname>Richardson</surname><given-names>M. A.</given-names></name><name><surname>Vickers</surname><given-names>A.</given-names></name><etal></etal></person-group><article-title>Acupuncture-point stimulation for chemotherapy-induced nausea or vomiting</article-title><source><italic>Cochrane Database of Systematic Reviews</italic></source><year>2006</year><volume>19</volume><issue>2</issue><pub-id pub-id-type="publisher-id">CD002285</pub-id><pub-id pub-id-type="other">2-s2.0-33745043057</pub-id></element-citation></ref><ref id="B5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kang</surname><given-names>M. K.</given-names></name><name><surname>Suh</surname><given-names>E. E.</given-names></name></person-group><article-title>The effects of P6 acupressure and guided imagery on nausea, vomiting, retching and anorexia of the patients with thyroid cancer undergoing radioactive iodine therapy</article-title><source><italic>Asian Oncology Nursing</italic></source><year>2013</year><volume>13</volume><issue>4</issue><fpage>p. 184</fpage><pub-id pub-id-type="doi">10.5388/aon.2013.13.4.184</pub-id></element-citation></ref><ref id="B6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jeon</surname><given-names>J.-H.</given-names></name><name><surname>Yoon</surname><given-names>J.</given-names></name><name><surname>Cho</surname><given-names>C.-K.</given-names></name><etal></etal></person-group><article-title>Effect of acupuncture for radioactive-iodine-induced anorexia in thyroid cancer patients: a randomized, double-blinded, sham-controlled pilot study</article-title><source><italic>Integrative Cancer Therapies</italic></source><year>2015</year><volume>14</volume><issue>3</issue><fpage>221</fpage><lpage>230</lpage><pub-id pub-id-type="doi">10.1177/1534735415570634</pub-id><pub-id pub-id-type="other">2-s2.0-84927943143</pub-id><pub-id pub-id-type="pmid">25691084</pub-id></element-citation></ref><ref id="B7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ruiz-Garcia</surname><given-names>V.</given-names></name><name><surname>Juan</surname><given-names>O.</given-names></name><name><surname>Perez Hoyos</surname><given-names>S.</given-names></name></person-group><article-title>Megestrol acetate: a systematic review usefulness about the weight gain in neoplastic patients with cachexia</article-title><source><italic>Medicina Clinica</italic></source><year>2002</year><volume>119</volume><issue>5</issue><fpage>166</fpage><lpage>170</lpage><pub-id pub-id-type="doi">10.1016/S0025-7753(02)73352-6</pub-id><pub-id pub-id-type="pmid">12200017</pub-id></element-citation></ref><ref id="B8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bruera</surname><given-names>E.</given-names></name><name><surname>Belzile</surname><given-names>M.</given-names></name><name><surname>Neumann</surname><given-names>C.</given-names></name><name><surname>Harsanyi</surname><given-names>Z.</given-names></name><name><surname>Babul</surname><given-names>N.</given-names></name><name><surname>Darke</surname><given-names>A.</given-names></name></person-group><article-title>A double-blind, crossover study of controlled-release metoclopramide and placebo for the chronic nausea and dyspepsia of advanced cancer</article-title><source><italic>Journal of Pain and Symptom Management</italic></source><year>2000</year><volume>19</volume><issue>6</issue><fpage>427</fpage><lpage>435</lpage><pub-id pub-id-type="other">2-s2.0-0033936966</pub-id><pub-id pub-id-type="doi">10.1016/S0885-3924(00)00138-X</pub-id><pub-id pub-id-type="pmid">10908823</pub-id></element-citation></ref><ref id="B9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Neary</surname><given-names>N. M.</given-names></name><name><surname>Small</surname><given-names>C. J.</given-names></name><name><surname>Wren</surname><given-names>A. M.</given-names></name><etal></etal></person-group><article-title>Ghrelin increases energy intake in cancer patients with impaired appetite: acute, randomized, placebo-controlled trial</article-title><source><italic>The Journal of Clinical Endocrinology &amp; Metabolism</italic></source><year>2004</year><volume>89</volume><issue>6</issue><fpage>2832</fpage><lpage>2836</lpage><pub-id pub-id-type="doi">10.1210/jc.2003-031768</pub-id><pub-id pub-id-type="other">2-s2.0-2942670638</pub-id><pub-id pub-id-type="pmid">15181065</pub-id></element-citation></ref><ref id="B10"><label>10</label><element-citation publication-type="book"><collab>Korea Food and Drug Administration</collab><source><italic>Research on Intake of Chinese Medicine by Korean</italic></source><year>2006</year><publisher-loc>Seoul, Korea</publisher-loc><publisher-name>Korea Food and Drug Administration</publisher-name></element-citation></ref><ref id="B11"><label>11</label><mixed-citation publication-type="other"><comment>Ministry of Food and Drug Safety, Online medicine library (<ext-link ext-link-type="uri" xlink:href="http://drug.mfds.go.kr">http://drug.mfds.go.kr</ext-link>), 2017, <ext-link ext-link-type="uri" xlink:href="http://drug.mfds.go.kr/html/bxsSearchDrugProduct_dsie.jsp?item_Seq=197900047">http://drug.mfds.go.kr/html/bxsSearchDrugProduct_dsie.jsp?item_Seq=197900047</ext-link></comment></mixed-citation></ref><ref id="B12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Utsuyama</surname><given-names>M.</given-names></name><name><surname>Seidlar</surname><given-names>H.</given-names></name><name><surname>Kitagawa</surname><given-names>M.</given-names></name><name><surname>Hirokawa</surname><given-names>K.</given-names></name></person-group><article-title>Immunological restoration and anti-tumor effect by Japanese herbal medicine in aged mice</article-title><source><italic>Mechanisms of Ageing and Development</italic></source><year>2001</year><volume>122</volume><issue>3</issue><fpage>341</fpage><lpage>352</lpage><pub-id pub-id-type="doi">10.1016/s0047-6374(00)00249-9</pub-id><pub-id pub-id-type="other">2-s2.0-0035047022</pub-id><pub-id pub-id-type="pmid">11311321</pub-id></element-citation></ref><ref id="B13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Choi</surname><given-names>Y. K.</given-names></name><name><surname>Jung</surname><given-names>K. Y.</given-names></name><name><surname>Woo</surname><given-names>S.-M.</given-names></name><etal></etal></person-group><article-title>Effect of sipjeondaebo-tang on cancer-induced anorexia and cachexia in ct-26 tumor-bearing mice</article-title><source><italic>Mediators of Inflammation</italic></source><year>2014</year><volume>2014</volume><fpage>10</fpage><pub-id pub-id-type="publisher-id">736563</pub-id><pub-id pub-id-type="doi">10.1155/2014/736563</pub-id><pub-id pub-id-type="other">2-s2.0-84901812850</pub-id></element-citation></ref><ref id="B14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cheon</surname><given-names>C.</given-names></name><name><surname>Park</surname><given-names>S.</given-names></name><name><surname>Park</surname><given-names>Y. L.</given-names></name><etal></etal></person-group><article-title>Sipjeondaebo-tang in patients with cancer with anorexia: A protocol for a pilot, randomised, controlled trial</article-title><source><italic>BMJ Open</italic></source><year>2016</year><volume>6</volume><issue>5</issue><pub-id pub-id-type="other">2-s2.0-84971326476</pub-id><pub-id pub-id-type="doi">10.1136/bmjopen-2016-011212</pub-id><pub-id pub-id-type="publisher-id">e011212</pub-id></element-citation></ref><ref id="B15"><label>15</label><element-citation publication-type="book"><collab>Ministry of Food and Drug Safety</collab><source><italic>The Korean Herbal Pharmacopoeia</italic></source><year>2017</year><publisher-loc>Seoul, Korea</publisher-loc><publisher-name>Ministry of Food and Drug Safety</publisher-name></element-citation></ref><ref id="B16"><label>16</label><element-citation publication-type="book"><collab>Ministry of Food and Drug Safety</collab><source><italic>The Korean Pharmacopoeia</italic></source><year>2017</year><publisher-loc>eoul, Korea</publisher-loc><publisher-name>Ministry of Food and Drug Safety</publisher-name></element-citation></ref><ref id="B17"><label>17</label><mixed-citation publication-type="other"><comment>FACIT, <ext-link ext-link-type="uri" xlink:href="http://www.facit.org.">http://www.facit.org.</ext-link>, 2017, <ext-link ext-link-type="uri" xlink:href="http://www.facit.org/LiteratureRetrieve.aspx?ID=42342">http://www.facit.org/LiteratureRetrieve.aspx?ID=42342</ext-link></comment></mixed-citation></ref><ref id="B18"><label>18</label><element-citation publication-type="other"><person-group person-group-type="author"><name><surname>Terasawa</surname><given-names>K.</given-names></name></person-group><comment>Kampo: Japanese-oriental medicine: insights from clinical cases. K.K. Standard McIntyre, 1993</comment></element-citation></ref><ref id="B19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fujitsuka</surname><given-names>N.</given-names></name><name><surname>Uezono</surname><given-names>Y.</given-names></name></person-group><article-title>Rikkunshito, a ghrelin potentiator, ameliorates anorexia-cachexia syndrome</article-title><source><italic>Frontiers in Pharmacology</italic></source><year>2014</year><volume>5, article 271</volume><pub-id pub-id-type="doi">10.3389/fphar.2014.00271</pub-id><pub-id pub-id-type="other">2-s2.0-84921761442</pub-id></element-citation></ref><ref id="B20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zanchi</surname><given-names>D.</given-names></name><name><surname>Depoorter</surname><given-names>A.</given-names></name><name><surname>Egloff</surname><given-names>L.</given-names></name><etal></etal></person-group><article-title>The impact of gut hormones on the neural circuit of appetite and satiety: A systematic review</article-title><source><italic>Neuroscience &amp; Biobehavioral Reviews</italic></source><year>2017</year><volume>80</volume><fpage>457</fpage><lpage>475</lpage><pub-id pub-id-type="doi">10.1016/j.neubiorev.2017.06.013</pub-id><pub-id pub-id-type="pmid">28669754</pub-id></element-citation></ref><ref id="B21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>De Silva</surname><given-names>A.</given-names></name><name><surname>Bloom</surname><given-names>S. R.</given-names></name></person-group><article-title>Gut hormones and appetite control: A focus on PYY and GLP-1 as therapeutic targets in obesity</article-title><source><italic>Gut and Liver</italic></source><year>2012</year><volume>6</volume><issue>1</issue><fpage>10</fpage><lpage>20</lpage><pub-id pub-id-type="other">2-s2.0-84856080046</pub-id><pub-id pub-id-type="doi">10.5009/gnl.2012.6.1.10</pub-id><pub-id pub-id-type="pmid">22375166</pub-id></element-citation></ref><ref id="B22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kogure</surname><given-names>T.</given-names></name><name><surname>Ltoh</surname><given-names>K.</given-names></name><name><surname>Tatsumi</surname><given-names>T.</given-names></name><etal></etal></person-group><article-title>The effect of Juzen-taiho-to/TJ-48 on the expression of killer-cell immunoglobulin-like receptors (CD158a/b) on peripheral lymphocytes in vitro experiment</article-title><source><italic>Phytomedicine</italic></source><year>2005</year><volume>12</volume><issue>5</issue><fpage>327</fpage><lpage>332</lpage><pub-id pub-id-type="other">2-s2.0-18144398531</pub-id><pub-id pub-id-type="doi">10.1016/j.phymed.2004.05.002</pub-id><pub-id pub-id-type="pmid">15957365</pub-id></element-citation></ref><ref id="B23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kamiyama</surname><given-names>H.</given-names></name><name><surname>Takano</surname><given-names>S.</given-names></name><name><surname>Ishikawa</surname><given-names>E.</given-names></name><name><surname>Tsuboi</surname><given-names>K.</given-names></name><name><surname>Matsumura</surname><given-names>A.</given-names></name></person-group><article-title>Anti-angiogenic and immunomodulatory effect of the herbal medicine “Juzen-taiho-to” on malignant glioma</article-title><source><italic>Biological &amp; Pharmaceutical Bulletin</italic></source><year>2005</year><volume>28</volume><issue>11</issue><fpage>2111</fpage><lpage>2116</lpage><pub-id pub-id-type="doi">10.1248/bpb.28.2111</pub-id><pub-id pub-id-type="other">2-s2.0-27744567135</pub-id><pub-id pub-id-type="pmid">16272699</pub-id></element-citation></ref><ref id="B24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ishikawa</surname><given-names>S.</given-names></name><name><surname>Ishikawa</surname><given-names>T.</given-names></name><name><surname>Tezuka</surname><given-names>C.</given-names></name><name><surname>Asano</surname><given-names>K.</given-names></name><name><surname>Sunagawa</surname><given-names>M.</given-names></name><name><surname>Hisamitsu</surname><given-names>T.</given-names></name></person-group><article-title>Efficacy of juzentaihoto for tumor immunotherapy in B16 melanoma metastasis model</article-title><source><italic>Evidence-Based Complementary and Alternative Medicine</italic></source><year>2017</year><volume>2017</volume><fpage>8</fpage><pub-id pub-id-type="publisher-id">6054706</pub-id><pub-id pub-id-type="doi">10.1155/2017/6054706</pub-id><pub-id pub-id-type="other">2-s2.0-85014485383</pub-id></element-citation></ref><ref id="B25"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ishikawa</surname><given-names>S.</given-names></name><name><surname>Ishikawa</surname><given-names>T.</given-names></name><name><surname>Asano</surname><given-names>K.</given-names></name><etal></etal></person-group><article-title>Suppressive effect of juzentaihoto on vascularization induced by b16 melanoma cells <italic>in vitro</italic> and <italic>in vivo</italic></article-title><source><italic>Evidence-Based Complementary and Alternative Medicine</italic></source><year>2012</year><volume>2012</volume><fpage>9</fpage><pub-id pub-id-type="publisher-id">945714</pub-id><pub-id pub-id-type="doi">10.1155/2012/945714</pub-id><pub-id pub-id-type="other">2-s2.0-84855170467</pub-id></element-citation></ref><ref id="B26"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ogawa</surname><given-names>K.</given-names></name><name><surname>Omatsu</surname><given-names>T.</given-names></name><name><surname>Matsumoto</surname><given-names>C.</given-names></name><etal></etal></person-group><article-title>Protective effect of the Japanese traditional medicine juzentaihoto on myelosuppression induced by the anticancer drug TS-1 and identification of a potential biomarker of this effect</article-title><source><italic>BMC Complementary and Alternative Medicine</italic></source><year>2012</year><volume>12, article no. 118</volume><pub-id pub-id-type="other">2-s2.0-84864661584</pub-id><pub-id pub-id-type="doi">10.1186/1472-6882-12-118</pub-id></element-citation></ref><ref id="B27"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nakamoto</surname><given-names>H.</given-names></name><name><surname>Mimura</surname><given-names>T.</given-names></name><name><surname>Honda</surname><given-names>N.</given-names></name></person-group><article-title>Orally administrated Juzen-taiho-to/TJ-48 ameliorates erythropoietin (rHuEPO)-resistant anemia in patients on hemodialysis</article-title><source><italic>Hemodialysis International</italic></source><year>2008</year><volume>12</volume><issue>2</issue><fpage>S9</fpage><lpage>S14</lpage><pub-id pub-id-type="other">2-s2.0-53349101229</pub-id><pub-id pub-id-type="doi">10.1111/j.1542-4758.2008.00317.x</pub-id><pub-id pub-id-type="pmid">18837771</pub-id></element-citation></ref><ref id="B28"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ishiura</surname><given-names>Y.</given-names></name><name><surname>Shiba</surname><given-names>Y.</given-names></name><name><surname>Terasaki</surname><given-names>Y.</given-names></name><etal></etal></person-group><article-title xml:lang="ja">Effect of Japanese traditional medicine, TJ-48, on the quality of life of patients with non-small cell lung cancer receiving outpatient chemotherapy</article-title><source><italic>Cancer &amp; Chemotherapy</italic></source><year>2016</year><volume>43</volume><issue>3</issue><fpage>331</fpage><lpage>334</lpage><pub-id pub-id-type="other">2-s2.0-84973410469</pub-id><pub-id pub-id-type="pmid">27067849</pub-id></element-citation></ref><ref id="B29"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ikemoto</surname><given-names>T.</given-names></name><name><surname>Shimada</surname><given-names>M.</given-names></name><name><surname>Iwahashi</surname><given-names>S.</given-names></name><etal></etal></person-group><article-title>Changes of immunological parameters with administration of Japanese Kampo medicine (Juzen-Taihoto/TJ-48) in patients with advanced pancreatic cancer</article-title><source><italic>International Journal of Clinical Oncology</italic></source><year>2014</year><volume>19</volume><issue>1</issue><fpage>81</fpage><lpage>86</lpage><pub-id pub-id-type="other">2-s2.0-84894563665</pub-id><pub-id pub-id-type="doi">10.1007/s10147-013-0529-6</pub-id><pub-id pub-id-type="pmid">23443635</pub-id></element-citation></ref><ref id="B30"><label>30</label><mixed-citation publication-type="other"><comment>World Health Organization Western Pacific Regional Office. WHO international standard terminologies on traditional medicine in the western pacific region. World Health Organization, Manila, 2007</comment></mixed-citation></ref><ref id="B31"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>J. J.</given-names></name><name><surname>Lee</surname><given-names>J. J.</given-names></name></person-group><article-title>A phase II study of an herbal decoction that includes astragali radix for cancer-associated anorexia in patients with advanced cancer</article-title><source><italic>Integrative Cancer Therapies</italic></source><year>2010</year><volume>9</volume><issue>1</issue><fpage>24</fpage><lpage>31</lpage><pub-id pub-id-type="other">2-s2.0-77953932843</pub-id><pub-id pub-id-type="doi">10.1177/1534735409359180</pub-id><pub-id pub-id-type="pmid">20150220</pub-id></element-citation></ref><ref id="B32"><label>32</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fujimoto</surname><given-names>K.</given-names></name><name><surname>Sakata</surname><given-names>T.</given-names></name><name><surname>Ishimaru</surname><given-names>T.</given-names></name><etal></etal></person-group><article-title>Attenuation of anorexia induced by heat or surgery during sustained administration of ginsenoside Rg1 into rat third ventricle</article-title><source><italic>Psychopharmacology</italic></source><year>1989</year><volume>99</volume><issue>2</issue><fpage>257</fpage><lpage>260</lpage><pub-id pub-id-type="other">2-s2.0-0024396811</pub-id><pub-id pub-id-type="doi">10.1007/BF00442819</pub-id><pub-id pub-id-type="pmid">2508164</pub-id></element-citation></ref><ref id="B33"><label>33</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cheng</surname><given-names>K.-C.</given-names></name><name><surname>Li</surname><given-names>Y.-X.</given-names></name><name><surname>Cheng</surname><given-names>J.-T.</given-names></name></person-group><article-title>The use of herbal medicine in cancer-related anorexia/cachexia treatment around the world</article-title><source><italic>Current Pharmaceutical Design</italic></source><year>2012</year><volume>18</volume><issue>31</issue><fpage>4819</fpage><lpage>4826</lpage><pub-id pub-id-type="doi">10.2174/138161212803216979</pub-id><pub-id pub-id-type="other">2-s2.0-84866360607</pub-id><pub-id pub-id-type="pmid">22632862</pub-id></element-citation></ref><ref id="B34"><label>34</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Woo</surname><given-names>S.-M.</given-names></name><name><surname>Choi</surname><given-names>Y. K.</given-names></name><name><surname>Kim</surname><given-names>A.-J.</given-names></name><etal></etal></person-group><article-title>Sip-jeon-dea-bo-tang, a traditional herbal medicine, ameliorates cisplatin-induced anorexia via the activation of JAK1/STAT3-mediated leptin and IL-6 production in the fat tissue of mice</article-title><source><italic>Molecular Medicine Reports</italic></source><year>2016</year><volume>13</volume><issue>4</issue><fpage>2967</fpage><lpage>2972</lpage><pub-id pub-id-type="other">2-s2.0-84963838145</pub-id><pub-id pub-id-type="doi">10.3892/mmr.2016.4889</pub-id><pub-id pub-id-type="pmid">26936678</pub-id></element-citation></ref></ref-list></back><floats-group><fig id="fig1" orientation="portrait" position="float"><label>Figure 1</label><caption><p>Participants flow chart.</p></caption><graphic xlink:href="ECAM2017-8780325.001"></graphic></fig><fig id="figbox1" orientation="portrait" position="float"><label>Box 1</label><caption><p>Participants eligibility criteria.</p></caption><graphic xlink:href="ECAM2017-8780325.figbox.001"></graphic></fig><table-wrap id="tab1" orientation="portrait" position="float"><label>Table 1</label><caption><p>General characteristics of participants.</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2" align="left" colspan="1">Variable</th><th align="center" rowspan="1" colspan="1">SJDBT group<break></break>(<italic>n</italic> = 16)</th><th align="center" rowspan="1" colspan="1">Placebo group<break></break>(<italic>n</italic> = 16)</th><th rowspan="2" align="center" colspan="1">
<italic>p</italic> value</th></tr><tr><th align="center" rowspan="1" colspan="1">Mean ± SD</th><th align="center" rowspan="1" colspan="1">Mean ± SD</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Age</td><td align="center" rowspan="1" colspan="1">54.1 ± 8.4</td><td align="center" rowspan="1" colspan="1">55.1 ± 8.9</td><td align="center" rowspan="1" colspan="1">0.718</td></tr><tr><td align="left" rowspan="1" colspan="1">Gender</td><td align="center" rowspan="1" colspan="1"> </td><td align="center" rowspan="1" colspan="1"> </td><td align="center" rowspan="1" colspan="1"> </td></tr><tr><td align="left" rowspan="1" colspan="1">Male</td><td align="center" rowspan="1" colspan="1">1 (6.2%)</td><td align="center" rowspan="1" colspan="1">1 (6.2%)</td><td rowspan="2" align="center" colspan="1">1.000</td></tr><tr><td align="left" rowspan="1" colspan="1">Female</td><td align="center" rowspan="1" colspan="1">15 (93.8%)</td><td align="center" rowspan="1" colspan="1">15 (93.8%)</td></tr><tr><td align="left" rowspan="1" colspan="1">Anthropometric measurements</td><td align="center" rowspan="1" colspan="1"> </td><td align="center" rowspan="1" colspan="1"> </td><td align="center" rowspan="1" colspan="1"> </td></tr><tr><td align="left" rowspan="1" colspan="1">Height, cm</td><td align="center" rowspan="1" colspan="1">159.2 ± 4.5</td><td align="center" rowspan="1" colspan="1">156.7 ± 5.4</td><td align="center" rowspan="1" colspan="1">0.178</td></tr><tr><td align="left" rowspan="1" colspan="1">Weight, kg</td><td align="center" rowspan="1" colspan="1">58.4 ± 9.0</td><td align="center" rowspan="1" colspan="1">59.1 ± 10.2</td><td align="center" rowspan="1" colspan="1">0.831</td></tr><tr><td align="left" rowspan="1" colspan="1">BMI</td><td align="center" rowspan="1" colspan="1">23.0 ± 3.2</td><td align="center" rowspan="1" colspan="1">24.1 ± 4.5</td><td align="center" rowspan="1" colspan="1">0.424</td></tr><tr><td align="left" rowspan="1" colspan="1">FAACT scale</td><td align="center" rowspan="1" colspan="1">92.6 ± 14.9</td><td align="center" rowspan="1" colspan="1">92.1 ± 22.9</td><td align="center" rowspan="1" colspan="1">0.942</td></tr><tr><td align="left" rowspan="1" colspan="1">FAACT ACS scale</td><td align="center" rowspan="1" colspan="1">29.5 ± 4.8</td><td align="center" rowspan="1" colspan="1">30.2 ± 5.5</td><td align="center" rowspan="1" colspan="1">0.711</td></tr><tr><td align="left" rowspan="1" colspan="1">Anorexia VAS</td><td align="center" rowspan="1" colspan="1">59.3 ± 16.8</td><td align="center" rowspan="1" colspan="1">58.8 ± 19.3</td><td align="center" rowspan="1" colspan="1">0.937</td></tr><tr><td align="left" rowspan="1" colspan="1">Systolic blood pressure (SBP), mmHg</td><td align="center" rowspan="1" colspan="1">110.1 ± 19.0</td><td align="center" rowspan="1" colspan="1">116.4 ± 12.8</td><td align="center" rowspan="1" colspan="1">0.275</td></tr><tr><td align="left" rowspan="1" colspan="1">Diastolic blood pressure (DBP), mmHg</td><td align="center" rowspan="1" colspan="1">70.6 ± 9.5</td><td align="center" rowspan="1" colspan="1">75.9 ± 11.7</td><td align="center" rowspan="1" colspan="1">0.168</td></tr><tr><td align="left" rowspan="1" colspan="1">Pulse, bpm</td><td align="center" rowspan="1" colspan="1">71.9 ± 9.7</td><td align="center" rowspan="1" colspan="1">71.6 ± 9.8</td><td align="center" rowspan="1" colspan="1">0.929</td></tr><tr><td align="left" rowspan="1" colspan="1">ACTH</td><td align="center" rowspan="1" colspan="1">17.8 ± 15.9</td><td align="center" rowspan="1" colspan="1">19.5 ± 17.9</td><td align="center" rowspan="1" colspan="1">0.771</td></tr><tr><td align="left" rowspan="1" colspan="1">Cortisol</td><td align="center" rowspan="1" colspan="1">10.2 ± 6.5</td><td align="center" rowspan="1" colspan="1">10.2 ± 5.4</td><td align="center" rowspan="1" colspan="1">0.995</td></tr><tr><td align="left" rowspan="1" colspan="1">Ghrelin</td><td align="center" rowspan="1" colspan="1">1121.2 ± 812.2</td><td align="center" rowspan="1" colspan="1">978.6 ± 361.4</td><td align="center" rowspan="1" colspan="1">0.528</td></tr><tr><td align="left" rowspan="1" colspan="1">Interleukin 6</td><td align="center" rowspan="1" colspan="1">1.9 ± 1.7</td><td align="center" rowspan="1" colspan="1">1.8 ± 1.9</td><td align="center" rowspan="1" colspan="1">0.883</td></tr><tr><td align="left" rowspan="1" colspan="1">ESR</td><td align="center" rowspan="1" colspan="1">19.9 ± 10.4</td><td align="center" rowspan="1" colspan="1">18.7 ± 8.9</td><td align="center" rowspan="1" colspan="1">0.717</td></tr><tr><td align="left" rowspan="1" colspan="1">CRP</td><td align="center" rowspan="1" colspan="1">0.1 ± 0.2</td><td align="center" rowspan="1" colspan="1">0.1 ± 0.2</td><td align="center" rowspan="1" colspan="1">0.983</td></tr><tr><td align="left" rowspan="1" colspan="1">Cancer type</td><td align="center" rowspan="1" colspan="1"> </td><td align="center" rowspan="1" colspan="1"> </td><td align="center" rowspan="1" colspan="1"> </td></tr><tr><td align="left" rowspan="1" colspan="1"> Breast cancer</td><td align="center" rowspan="1" colspan="1">3 (18.8%)</td><td align="center" rowspan="1" colspan="1">4 (25.0%)</td><td rowspan="6" align="center" colspan="1">0.267</td></tr><tr><td align="left" rowspan="1" colspan="1"> Cervical cancer</td><td align="center" rowspan="1" colspan="1">2 (12.5%)</td><td align="center" rowspan="1" colspan="1">0 (0.0%)</td></tr><tr><td align="left" rowspan="1" colspan="1"> Colon cancer</td><td align="center" rowspan="1" colspan="1">1 (6.2%)</td><td align="center" rowspan="1" colspan="1">1 (6.2%)</td></tr><tr><td align="left" rowspan="1" colspan="1"> Gastric cancer</td><td align="center" rowspan="1" colspan="1">3 (18.8%)</td><td align="center" rowspan="1" colspan="1">0 (0.0%)</td></tr><tr><td align="left" rowspan="1" colspan="1"> Lung cancer</td><td align="center" rowspan="1" colspan="1">1 (6.2%)</td><td align="center" rowspan="1" colspan="1">3 (18.8%)</td></tr><tr><td align="left" rowspan="1" colspan="1"> Thyroid cancer</td><td align="center" rowspan="1" colspan="1">6 (37.5%)</td><td align="center" rowspan="1" colspan="1">8 (50.0%)</td></tr><tr><td align="left" rowspan="1" colspan="1">Anticancer therapy</td><td align="center" rowspan="1" colspan="1"> </td><td align="center" rowspan="1" colspan="1"> </td><td align="center" rowspan="1" colspan="1"> </td></tr><tr><td align="left" rowspan="1" colspan="1"> Chemo- and radiotherapy</td><td align="center" rowspan="1" colspan="1">3 (18.8%)</td><td align="center" rowspan="1" colspan="1">0 (0.0%)</td><td rowspan="4" align="center" colspan="1">0.239</td></tr><tr><td align="left" rowspan="1" colspan="1"> Chemotherapy only</td><td align="center" rowspan="1" colspan="1">3 (18.8%)</td><td align="center" rowspan="1" colspan="1">4 (25.0%)</td></tr><tr><td align="left" rowspan="1" colspan="1"> Radiotherapy only</td><td align="center" rowspan="1" colspan="1">3 (18.8%)</td><td align="center" rowspan="1" colspan="1">6 (37.5%)</td></tr><tr><td align="left" rowspan="1" colspan="1"> None</td><td align="center" rowspan="1" colspan="1">7 (43.8%)</td><td align="center" rowspan="1" colspan="1">6 (37.5%)</td></tr></tbody></table></table-wrap><table-wrap id="tab2" orientation="portrait" position="float"><label>Table 2</label><caption><p>Changes from baseline to the end of the study on anorexia.</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2" align="left" colspan="1">Variable</th><th rowspan="2" align="center" colspan="1">Period</th><th align="center" rowspan="1" colspan="1">SJDBT group (<italic>n</italic> = 16)</th><th align="center" rowspan="1" colspan="1">Placebo group (<italic>n</italic> = 16)</th><th rowspan="2" align="center" colspan="1">
<italic>p</italic>
</th><th rowspan="2" align="center" colspan="1">Group effect</th><th rowspan="2" align="center" colspan="1">Period effect</th></tr><tr><th align="center" rowspan="1" colspan="1">Mean ± SD</th><th align="center" rowspan="1" colspan="1">Mean ± SD</th></tr></thead><tbody><tr><td rowspan="5" align="left" colspan="1">FAACT <break></break>ACS scale</td><td align="center" rowspan="1" colspan="1">0 weeks</td><td align="center" rowspan="1" colspan="1">29.50 ± 4.84</td><td align="center" rowspan="1" colspan="1">30.19 ± 5.54</td><td align="center" rowspan="1" colspan="1"> </td><td rowspan="3" align="center" colspan="1">0.456</td><td rowspan="3" align="center" colspan="1">0.028</td></tr><tr><td align="center" rowspan="1" colspan="1">2 weeks</td><td align="center" rowspan="1" colspan="1">33.19 ± 4.86</td><td align="center" rowspan="1" colspan="1">31.19 ± 4.64</td><td align="center" rowspan="1" colspan="1"> </td></tr><tr><td align="center" rowspan="1" colspan="1">4 weeks</td><td align="center" rowspan="1" colspan="1">34.13 ± 6.03</td><td align="center" rowspan="1" colspan="1">32.94 ± 6.56</td><td align="center" rowspan="1" colspan="1"> </td></tr><tr><td align="center" rowspan="1" colspan="1">Δ(0–4<sup>week</sup>)</td><td align="center" rowspan="1" colspan="1">−4.63 ± 4.50</td><td align="center" rowspan="1" colspan="1">−2.75 ± 4.43</td><td align="center" rowspan="1" colspan="1">0.245</td><td align="center" rowspan="1" colspan="1"> </td><td align="center" rowspan="1" colspan="1"> </td></tr><tr><td align="center" rowspan="1" colspan="1">ANOVA</td><td colspan="3" align="center" rowspan="1">Period X group interaction: <italic>p</italic> = 0.602</td><td align="center" rowspan="1" colspan="1"> </td><td align="center" rowspan="1" colspan="1"> </td></tr><tr><td colspan="7" rowspan="1">
<hr></hr>
</td></tr><tr><td rowspan="5" align="left" colspan="1">FAACT</td><td align="center" rowspan="1" colspan="1">0 weeks</td><td align="center" rowspan="1" colspan="1">92.56 ± 14.94</td><td align="center" rowspan="1" colspan="1">92.06 ± 22.89</td><td align="center" rowspan="1" colspan="1"> </td><td align="center" rowspan="1" colspan="1"> </td><td align="center" rowspan="1" colspan="1"> </td></tr><tr><td align="center" rowspan="1" colspan="1">2 weeks</td><td align="center" rowspan="1" colspan="1">104.13 ± 17.51</td><td align="center" rowspan="1" colspan="1">94.44 ± 22.95</td><td align="center" rowspan="1" colspan="1"> </td><td align="center" rowspan="1" colspan="1">0.176</td><td align="center" rowspan="1" colspan="1">0.118</td></tr><tr><td align="center" rowspan="1" colspan="1">4 weeks</td><td align="center" rowspan="1" colspan="1">106.69 ± 20.00</td><td align="center" rowspan="1" colspan="1">99.44 ± 25.15</td><td align="center" rowspan="1" colspan="1"> </td><td align="center" rowspan="1" colspan="1"> </td><td align="center" rowspan="1" colspan="1"> </td></tr><tr><td align="center" rowspan="1" colspan="1">Δ(0–4<sup>week</sup>)</td><td align="center" rowspan="1" colspan="1">−14.13 ± 13.73</td><td align="center" rowspan="1" colspan="1">−7.38 ± 10.13</td><td align="center" rowspan="1" colspan="1">0.124</td><td align="center" rowspan="1" colspan="1"> </td><td align="center" rowspan="1" colspan="1"> </td></tr><tr><td align="center" rowspan="1" colspan="1">ANOVA</td><td colspan="3" align="center" rowspan="1">Period X group interaction: <italic>p</italic> = 0.661</td><td align="center" rowspan="1" colspan="1"> </td><td align="center" rowspan="1" colspan="1"> </td></tr><tr><td colspan="7" rowspan="1">
<hr></hr>
</td></tr><tr><td rowspan="5" align="left" colspan="1">Anorexia <break></break>VAS</td><td align="center" rowspan="1" colspan="1">0 weeks</td><td align="center" rowspan="1" colspan="1">59.34 ± 16.78</td><td align="center" rowspan="1" colspan="1">58.83 ± 19.34</td><td align="center" rowspan="1" colspan="1"> </td><td align="center" rowspan="1" colspan="1"> </td><td align="center" rowspan="1" colspan="1"> </td></tr><tr><td align="center" rowspan="1" colspan="1">2 weeks</td><td align="center" rowspan="1" colspan="1">39.56 ± 12.46</td><td align="center" rowspan="1" colspan="1">39.80 ± 23.18</td><td align="center" rowspan="1" colspan="1"> </td><td align="center" rowspan="1" colspan="1">0.600</td><td align="center" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td align="center" rowspan="1" colspan="1">4 weeks</td><td align="center" rowspan="1" colspan="1">33.57 ± 19.34</td><td align="center" rowspan="1" colspan="1">40.38 ± 27.29</td><td align="center" rowspan="1" colspan="1"> </td><td align="center" rowspan="1" colspan="1"> </td><td align="center" rowspan="1" colspan="1"> </td></tr><tr><td align="center" rowspan="1" colspan="1">Δ(0–4<sup>week</sup>)</td><td align="center" rowspan="1" colspan="1">25.78 ± 24.04</td><td align="center" rowspan="1" colspan="1">18.45 ± 18.99</td><td align="center" rowspan="1" colspan="1">0.346</td><td align="center" rowspan="1" colspan="1"> </td><td align="center" rowspan="1" colspan="1"> </td></tr><tr><td align="center" rowspan="1" colspan="1">ANOVA</td><td colspan="3" align="center" rowspan="1">Period X group interaction: <italic>p</italic> = 0.730</td><td align="center" rowspan="1" colspan="1"> </td><td align="center" rowspan="1" colspan="1"> </td></tr></tbody></table><table-wrap-foot><fn><p>FAACT: Functional Assessment of Anorexia Cachexia Therapy; ACS: Anorexia-Cachexia Subscale; VAS: Visual Analogue Scale; <italic>p</italic> represents <italic>p</italic> value of comparison between mean difference of SJDBT group and placebo group.</p></fn></table-wrap-foot></table-wrap><table-wrap id="tab3" orientation="portrait" position="float"><label>Table 3</label><caption><p>Changes from baseline to the end of the study on clinical laboratory tests.</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2" align="left" colspan="1">Variable</th><th rowspan="2" align="center" colspan="1">Period</th><th colspan="2" align="center" rowspan="1">SJDBT group (<italic>n</italic> = 16)</th><th colspan="2" align="center" rowspan="1">Placebo group (<italic>n</italic> = 16)</th><th rowspan="2" align="center" colspan="1">
<italic>p</italic>
</th></tr><tr><th align="center" rowspan="1" colspan="1">Mean ± SD</th><th align="center" rowspan="1" colspan="1">(<italic>p</italic><sub>intra</sub>)</th><th align="center" rowspan="1" colspan="1">Mean ± SD</th><th align="center" rowspan="1" colspan="1">(<italic>p</italic><sub>intra</sub>)</th></tr></thead><tbody><tr><td rowspan="3" align="left" colspan="1">ACTH</td><td align="center" rowspan="1" colspan="1">0 weeks</td><td align="center" rowspan="1" colspan="1">17.76 ± 15.94</td><td align="center" rowspan="1" colspan="1"> </td><td align="center" rowspan="1" colspan="1">19.52 ± 17.95</td><td align="center" rowspan="1" colspan="1"> </td><td align="center" rowspan="1" colspan="1">0.771</td></tr><tr><td align="center" rowspan="1" colspan="1">4 weeks</td><td align="center" rowspan="1" colspan="1">15.28 ± 8.94</td><td align="center" rowspan="1" colspan="1">0.468</td><td align="center" rowspan="1" colspan="1">15.12 ± 10.58</td><td align="center" rowspan="1" colspan="1">0.199</td><td align="center" rowspan="1" colspan="1">0.963</td></tr><tr><td align="center" rowspan="1" colspan="1">Δ(0–4<sup>week</sup>)</td><td align="center" rowspan="1" colspan="1">2.48 ± 13.29</td><td align="center" rowspan="1" colspan="1"> </td><td align="center" rowspan="1" colspan="1">4.40 ± 13.10</td><td align="center" rowspan="1" colspan="1"> </td><td align="center" rowspan="1" colspan="1">0.683</td></tr><tr><td colspan="7" rowspan="1">
<hr></hr>
</td></tr><tr><td rowspan="3" align="left" colspan="1">Cortisol</td><td align="center" rowspan="1" colspan="1">0 weeks</td><td align="center" rowspan="1" colspan="1">10.22 ± 6.45</td><td align="center" rowspan="1" colspan="1"> </td><td align="center" rowspan="1" colspan="1">10.23 ± 5.44</td><td align="center" rowspan="1" colspan="1"> </td><td align="center" rowspan="1" colspan="1">0.995</td></tr><tr><td align="center" rowspan="1" colspan="1">4 weeks</td><td align="center" rowspan="1" colspan="1">10.19 ± 5.20</td><td align="center" rowspan="1" colspan="1">0.982</td><td align="center" rowspan="1" colspan="1">8.60 ± 4.19</td><td align="center" rowspan="1" colspan="1">0.316</td><td align="center" rowspan="1" colspan="1">0.350</td></tr><tr><td align="center" rowspan="1" colspan="1">Δ(0–4<sup>week</sup>)</td><td align="center" rowspan="1" colspan="1">0.03 ± 5.25</td><td align="center" rowspan="1" colspan="1"> </td><td align="center" rowspan="1" colspan="1">1.63 ± 6.28</td><td align="center" rowspan="1" colspan="1"> </td><td align="center" rowspan="1" colspan="1">0.441</td></tr><tr><td colspan="7" rowspan="1">
<hr></hr>
</td></tr><tr><td rowspan="3" align="left" colspan="1">Ghrelin</td><td align="center" rowspan="1" colspan="1">0 weeks</td><td align="center" rowspan="1" colspan="1">1121.19 ± 812.25</td><td align="center" rowspan="1" colspan="1"> </td><td align="center" rowspan="1" colspan="1">978.63 ± 361.44</td><td align="center" rowspan="1" colspan="1"> </td><td align="center" rowspan="1" colspan="1">0.526</td></tr><tr><td align="center" rowspan="1" colspan="1">4 weeks</td><td align="center" rowspan="1" colspan="1">1252.69 ± 753.61</td><td align="center" rowspan="1" colspan="1">0.036</td><td align="center" rowspan="1" colspan="1">1255.50 ± 724.46</td><td align="center" rowspan="1" colspan="1">0.044</td><td align="center" rowspan="1" colspan="1">0.992</td></tr><tr><td align="center" rowspan="1" colspan="1">Δ(0–4<sup>week</sup>)</td><td align="center" rowspan="1" colspan="1">−131.51 ± 228.54</td><td align="center" rowspan="1" colspan="1"> </td><td align="center" rowspan="1" colspan="1">−276.87 ± 504.58</td><td align="center" rowspan="1" colspan="1"> </td><td align="center" rowspan="1" colspan="1">0.302</td></tr><tr><td colspan="7" rowspan="1">
<hr></hr>
</td></tr><tr><td rowspan="3" align="left" colspan="1">IL-6</td><td align="center" rowspan="1" colspan="1">0 weeks</td><td align="center" rowspan="1" colspan="1">1.93 ± 1.69</td><td align="center" rowspan="1" colspan="1"> </td><td align="center" rowspan="1" colspan="1">1.83 ± 1.87</td><td align="center" rowspan="1" colspan="1"> </td><td align="center" rowspan="1" colspan="1">0.883</td></tr><tr><td align="center" rowspan="1" colspan="1">4 weeks</td><td align="center" rowspan="1" colspan="1">2.61 ± 2.42</td><td align="center" rowspan="1" colspan="1">0.213</td><td align="center" rowspan="1" colspan="1">2.60 ± 4.55</td><td align="center" rowspan="1" colspan="1">0.412</td><td align="center" rowspan="1" colspan="1">0.996</td></tr><tr><td align="center" rowspan="1" colspan="1">Δ(0–4<sup>week</sup>)</td><td align="center" rowspan="1" colspan="1">−0.68 ± 2.09</td><td align="center" rowspan="1" colspan="1"> </td><td align="center" rowspan="1" colspan="1">−0.77 ± 3.64</td><td align="center" rowspan="1" colspan="1"> </td><td align="center" rowspan="1" colspan="1">0.934</td></tr><tr><td colspan="7" rowspan="1">
<hr></hr>
</td></tr><tr><td rowspan="3" align="left" colspan="1">ESR</td><td align="center" rowspan="1" colspan="1">0 weeks</td><td align="center" rowspan="1" colspan="1">19.94 ± 10.36</td><td align="center" rowspan="1" colspan="1"> </td><td align="center" rowspan="1" colspan="1">18.69 ± 8.90</td><td align="center" rowspan="1" colspan="1"> </td><td align="center" rowspan="1" colspan="1">0.717</td></tr><tr><td align="center" rowspan="1" colspan="1">4 weeks</td><td align="center" rowspan="1" colspan="1">20.75 ± 11.46</td><td align="center" rowspan="1" colspan="1">0.572</td><td align="center" rowspan="1" colspan="1">18.63 ± 7.47</td><td align="center" rowspan="1" colspan="1">0.972</td><td align="center" rowspan="1" colspan="1">0.539</td></tr><tr><td align="center" rowspan="1" colspan="1">Δ(0–4<sup>week</sup>)</td><td align="center" rowspan="1" colspan="1">−0.81 ± 5.62</td><td align="center" rowspan="1" colspan="1"> </td><td align="center" rowspan="1" colspan="1">0.06 ± 7.07</td><td align="center" rowspan="1" colspan="1"> </td><td align="center" rowspan="1" colspan="1">0.701</td></tr><tr><td colspan="7" rowspan="1">
<hr></hr>
</td></tr><tr><td rowspan="3" align="left" colspan="1">CRP</td><td align="center" rowspan="1" colspan="1">0 weeks</td><td align="center" rowspan="1" colspan="1">0.08 ± 0.17</td><td align="center" rowspan="1" colspan="1"> </td><td align="center" rowspan="1" colspan="1">0.08 ± 0.16</td><td align="center" rowspan="1" colspan="1"> </td><td align="center" rowspan="1" colspan="1">0.983</td></tr><tr><td align="center" rowspan="1" colspan="1">4 weeks</td><td align="center" rowspan="1" colspan="1">0.10 ± 0.27</td><td align="center" rowspan="1" colspan="1">0.741</td><td align="center" rowspan="1" colspan="1">0.11 ± 0.20</td><td align="center" rowspan="1" colspan="1">0.570</td><td align="center" rowspan="1" colspan="1">0.907</td></tr><tr><td align="center" rowspan="1" colspan="1">Δ(0–4<sup>week</sup>)</td><td align="center" rowspan="1" colspan="1">−0.02 ± 0.28</td><td align="center" rowspan="1" colspan="1"> </td><td align="center" rowspan="1" colspan="1">−0.03 ± 0.22</td><td align="center" rowspan="1" colspan="1"> </td><td align="center" rowspan="1" colspan="1">0.921</td></tr></tbody></table><table-wrap-foot><fn><p>ACTH: adrenocorticotropic hormone; IL-6: interleukin 6; ESR: erythrocyte sedimentation rate; CRP: C-reactive protein; (<italic>p</italic><sub>intra</sub>) represents <italic>p</italic> value of comparison between 0 weeks and 4 weeks within each group; <italic>p</italic> represents <italic>p</italic> value of comparison between SJDBT group and placebo group in each period.</p></fn></table-wrap-foot></table-wrap><table-wrap id="tab4" orientation="portrait" position="float"><label>Table 4</label><caption><p>Changes from baseline to the end of the study on qi and blood deficiency.</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2" align="left" colspan="1">Variable</th><th rowspan="2" align="center" colspan="1">Period</th><th colspan="2" align="center" rowspan="1">SJDBT group (<italic>n</italic> = 16)</th><th colspan="2" align="center" rowspan="1">Placebo group (<italic>n</italic> = 16)</th><th rowspan="2" align="center" colspan="1">
<italic>p</italic>
</th></tr><tr><th align="center" rowspan="1" colspan="1">Mean ± SD</th><th align="center" rowspan="1" colspan="1">(<italic>p</italic><sub>intra</sub>)</th><th align="center" rowspan="1" colspan="1">Mean ± SD</th><th align="center" rowspan="1" colspan="1">(<italic>p</italic><sub>intra</sub>)</th></tr></thead><tbody><tr><td rowspan="3" align="left" colspan="1">Qi</td><td align="center" rowspan="1" colspan="1">0 weeks</td><td align="center" rowspan="1" colspan="1">56.25 ± 9.90</td><td align="center" rowspan="1" colspan="1"> </td><td align="center" rowspan="1" colspan="1">58.56 ± 12.01</td><td align="center" rowspan="1" colspan="1"> </td><td align="center" rowspan="1" colspan="1">0.557</td></tr><tr><td align="center" rowspan="1" colspan="1">4 weeks</td><td align="center" rowspan="1" colspan="1">38.75 ± 14.54</td><td align="center" rowspan="1" colspan="1">0.002</td><td align="center" rowspan="1" colspan="1">39.19 ± 14.31</td><td align="center" rowspan="1" colspan="1">&lt;0.001</td><td align="center" rowspan="1" colspan="1">0.932</td></tr><tr><td align="center" rowspan="1" colspan="1">Δ(0–4<sup>week</sup>)</td><td align="center" rowspan="1" colspan="1">17.50 ± 18.18</td><td align="center" rowspan="1" colspan="1"> </td><td align="center" rowspan="1" colspan="1">19.38 ± 15.71</td><td align="center" rowspan="1" colspan="1"> </td><td align="center" rowspan="1" colspan="1">0.757</td></tr><tr><td colspan="7" rowspan="1">
<hr></hr>
</td></tr><tr><td rowspan="3" align="left" colspan="1">Blood</td><td align="center" rowspan="1" colspan="1">0 weeks</td><td align="center" rowspan="1" colspan="1">47.56 ± 13.16</td><td align="center" rowspan="1" colspan="1"> </td><td align="center" rowspan="1" colspan="1">47.94 ± 16.63</td><td align="center" rowspan="1" colspan="1"> </td><td align="center" rowspan="1" colspan="1">0.944</td></tr><tr><td align="center" rowspan="1" colspan="1">4 weeks</td><td align="center" rowspan="1" colspan="1">36.63 ± 15.31</td><td align="center" rowspan="1" colspan="1">0.034</td><td align="center" rowspan="1" colspan="1">36.81 ± 18.57</td><td align="center" rowspan="1" colspan="1">0.076</td><td align="center" rowspan="1" colspan="1">0.975</td></tr><tr><td align="center" rowspan="1" colspan="1">Δ(0–4<sup>week</sup>)</td><td align="center" rowspan="1" colspan="1">10.94 ± 18.76</td><td align="center" rowspan="1" colspan="1"> </td><td align="center" rowspan="1" colspan="1">11.13 ± 23.34</td><td align="center" rowspan="1" colspan="1"> </td><td align="center" rowspan="1" colspan="1">0.980</td></tr></tbody></table><table-wrap-foot><fn><p>(<italic>p</italic><sub>intra</sub>) represents <italic>p</italic> value of comparison between 0 weeks and 4 weeks within each group; <italic>p</italic> represents <italic>p</italic> value of comparison between SJDBT group and placebo group in each period.</p></fn></table-wrap-foot></table-wrap><table-wrap id="tab5" orientation="portrait" position="float"><label>Table 5</label><caption><p>The result for safety analysis.</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2" align="left" colspan="1">Variable</th><th rowspan="2" align="center" colspan="1">Period</th><th colspan="2" align="center" rowspan="1">SJDBT group (<italic>n</italic> = 16)</th><th colspan="2" align="center" rowspan="1">Placebo group (<italic>n</italic> = 16)</th><th rowspan="2" align="center" colspan="1">
<italic>p</italic>
</th></tr><tr><th align="center" rowspan="1" colspan="1">Mean ± SD</th><th align="center" rowspan="1" colspan="1">(<italic>p</italic><sub>intra</sub>)</th><th align="center" rowspan="1" colspan="1">Mean ± SD</th><th align="center" rowspan="1" colspan="1">(<italic>p</italic><sub>intra</sub>)</th></tr></thead><tbody><tr><td rowspan="3" align="left" colspan="1">SBP, mmHg</td><td align="center" rowspan="1" colspan="1">0 weeks</td><td align="center" rowspan="1" colspan="1">110.06 ± 18.99</td><td align="center" rowspan="1" colspan="1"> </td><td align="center" rowspan="1" colspan="1">116.44 ± 12.83</td><td align="center" rowspan="1" colspan="1"> </td><td align="center" rowspan="1" colspan="1">0.275</td></tr><tr><td align="center" rowspan="1" colspan="1">2 weeks</td><td align="center" rowspan="1" colspan="1">111.94 ± 16.38</td><td align="center" rowspan="1" colspan="1">0.471</td><td align="center" rowspan="1" colspan="1">114.38 ± 16.04</td><td align="center" rowspan="1" colspan="1">0.445</td><td align="center" rowspan="1" colspan="1">0.674</td></tr><tr><td align="center" rowspan="1" colspan="1">4 weeks</td><td align="center" rowspan="1" colspan="1">112.50 ± 17.75</td><td align="center" rowspan="1" colspan="1">0.397</td><td align="center" rowspan="1" colspan="1">116.81 ± 12.30</td><td align="center" rowspan="1" colspan="1">0.893</td><td align="center" rowspan="1" colspan="1">0.431</td></tr><tr><td colspan="7" rowspan="1">
<hr></hr>
</td></tr><tr><td rowspan="3" align="left" colspan="1">DBP, mmHg</td><td align="center" rowspan="1" colspan="1">0 weeks</td><td align="center" rowspan="1" colspan="1">70.63 ± 9.45</td><td align="center" rowspan="1" colspan="1"> </td><td align="center" rowspan="1" colspan="1">75.94 ± 11.68</td><td align="center" rowspan="1" colspan="1"> </td><td align="center" rowspan="1" colspan="1">0.168</td></tr><tr><td align="center" rowspan="1" colspan="1">2 weeks</td><td align="center" rowspan="1" colspan="1">73.81 ± 9.03</td><td align="center" rowspan="1" colspan="1">0.140</td><td align="center" rowspan="1" colspan="1">70.13 ± 11.48</td><td align="center" rowspan="1" colspan="1">0.038</td><td align="center" rowspan="1" colspan="1">0.321</td></tr><tr><td align="center" rowspan="1" colspan="1">4 weeks</td><td align="center" rowspan="1" colspan="1">75.31 ± 12.47</td><td align="center" rowspan="1" colspan="1">0.047</td><td align="center" rowspan="1" colspan="1">76.19 ± 10.06</td><td align="center" rowspan="1" colspan="1">0.922</td><td align="center" rowspan="1" colspan="1">0.829</td></tr><tr><td colspan="7" rowspan="1">
<hr></hr>
</td></tr><tr><td rowspan="3" align="left" colspan="1">Pulse, bpm</td><td align="center" rowspan="1" colspan="1">0 weeks</td><td align="center" rowspan="1" colspan="1">71.94 ± 9.74</td><td align="center" rowspan="1" colspan="1"> </td><td align="center" rowspan="1" colspan="1">71.63 ± 9.82</td><td align="center" rowspan="1" colspan="1"> </td><td align="center" rowspan="1" colspan="1">0.929</td></tr><tr><td align="center" rowspan="1" colspan="1">2 weeks</td><td align="center" rowspan="1" colspan="1">73.38 ± 11.98</td><td align="center" rowspan="1" colspan="1">0.477</td><td align="center" rowspan="1" colspan="1">73.81 ± 6.24</td><td align="center" rowspan="1" colspan="1">0.216</td><td align="center" rowspan="1" colspan="1">0.898</td></tr><tr><td align="center" rowspan="1" colspan="1">4 weeks</td><td align="center" rowspan="1" colspan="1">75.94 ± 9.94</td><td align="center" rowspan="1" colspan="1">0.128</td><td align="center" rowspan="1" colspan="1">70.38 ± 7.88</td><td align="center" rowspan="1" colspan="1">0.460</td><td align="center" rowspan="1" colspan="1">0.090</td></tr><tr><td colspan="7" rowspan="1">
<hr></hr>
</td></tr><tr><td rowspan="2" align="left" colspan="1">AST, IU/L</td><td align="center" rowspan="1" colspan="1">0 weeks</td><td align="center" rowspan="1" colspan="1">20.94 ± 6.81</td><td align="center" rowspan="1" colspan="1"> </td><td align="center" rowspan="1" colspan="1">21.38 ± 5.44</td><td align="center" rowspan="1" colspan="1"> </td><td align="center" rowspan="1" colspan="1">0.842</td></tr><tr><td align="center" rowspan="1" colspan="1">4 weeks</td><td align="center" rowspan="1" colspan="1">24.94 ± 14.09</td><td align="center" rowspan="1" colspan="1">0.157</td><td align="center" rowspan="1" colspan="1">23.06 ± 7.13</td><td align="center" rowspan="1" colspan="1">0.217</td><td align="center" rowspan="1" colspan="1">0.638</td></tr><tr><td colspan="7" rowspan="1">
<hr></hr>
</td></tr><tr><td rowspan="2" align="left" colspan="1">ALT, IU/L</td><td align="center" rowspan="1" colspan="1">0 weeks</td><td align="center" rowspan="1" colspan="1">17.31 ± 9.41</td><td align="center" rowspan="1" colspan="1"> </td><td align="center" rowspan="1" colspan="1">21.63 ± 11.53</td><td align="center" rowspan="1" colspan="1"> </td><td align="center" rowspan="1" colspan="1">0.256</td></tr><tr><td align="center" rowspan="1" colspan="1">4 weeks</td><td align="center" rowspan="1" colspan="1">20.13 ± 13.39</td><td align="center" rowspan="1" colspan="1">0.210</td><td align="center" rowspan="1" colspan="1">22.50 ± 10.92</td><td align="center" rowspan="1" colspan="1">0.609</td><td align="center" rowspan="1" colspan="1">0.587</td></tr><tr><td colspan="7" rowspan="1">
<hr></hr>
</td></tr><tr><td rowspan="2" align="left" colspan="1">BUN, mg/dL</td><td align="center" rowspan="1" colspan="1">0 weeks</td><td align="center" rowspan="1" colspan="1">12.19 ± 2.85</td><td align="center" rowspan="1" colspan="1"> </td><td align="center" rowspan="1" colspan="1">13.95 ± 3.80</td><td align="center" rowspan="1" colspan="1"> </td><td align="center" rowspan="1" colspan="1">0.149</td></tr><tr><td align="center" rowspan="1" colspan="1">4 weeks</td><td align="center" rowspan="1" colspan="1">13.44 ± 2.84</td><td align="center" rowspan="1" colspan="1">0.138</td><td align="center" rowspan="1" colspan="1">13.38 ± 3.07</td><td align="center" rowspan="1" colspan="1">0.489</td><td align="center" rowspan="1" colspan="1">0.953</td></tr><tr><td colspan="7" rowspan="1">
<hr></hr>
</td></tr><tr><td rowspan="2" align="left" colspan="1">Cre, mg/dL</td><td align="center" rowspan="1" colspan="1">0 weeks</td><td align="center" rowspan="1" colspan="1">0.75 ± 0.10</td><td align="center" rowspan="1" colspan="1"> </td><td align="center" rowspan="1" colspan="1">0.80 ± 0.11</td><td align="center" rowspan="1" colspan="1"> </td><td align="center" rowspan="1" colspan="1">0.242</td></tr><tr><td align="center" rowspan="1" colspan="1">4 weeks</td><td align="center" rowspan="1" colspan="1">0.76 ± 0.08</td><td align="center" rowspan="1" colspan="1">0.513</td><td align="center" rowspan="1" colspan="1">0.79 ± 0.09</td><td align="center" rowspan="1" colspan="1">0.779</td><td align="center" rowspan="1" colspan="1">0.320</td></tr></tbody></table><table-wrap-foot><fn><p>SBP: systolic blood pressure; DBP: diastolic blood pressure; AST: aspartate aminotransferase; ALT: alanine transferase; BUN: blood urea nitrogen; Cre: creatinine; (<italic>p</italic><sub>intra</sub>) represents <italic>p</italic> value of comparison between 0 weeks and <italic>n</italic> weeks within each group; <italic>p</italic> represents <italic>p</italic> value of comparison between SJDBT group and placebo group in each period.</p></fn></table-wrap-foot></table-wrap></floats-group></article>